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Abstract
The mature FMS receptor has been demonstrated here as being subject to constitutive loss
as shown by S35 methionine labelling, live antibody labelling surface loss, surface biotinylation
and FACS analysis with a half-life estimated at between 1 and 2 hours. This receptor turnover
has been shown to be independent of kinase activity by the use of kinase impaired mutants
and also a highly specific FMS kinase inhibitor, GW2580 that is able to inhibit the ligand-
induced downregulation of FMS. The intracellular domain of the FMS receptor is believed not
to be involved in the proteins constitutive downregulation from experiments performed here
using domain deletion mutations and broad spectrum inhibition of other intracellular kinases.
All experiments demonstrated FMS constitutive loss at the same rate as the wild-type and
untreated receptor. The constitutive turnover has been further demonstrated to be distinct
from FMS downregulation occurring via shedding and RIP mediated by ADAM17 and the
γ-secretase complex respectively.
We have demonstrated that the mechanism of receptor downregulation is independent of clathrin,
caveolin and dynamin. FMS has been demonstrated here to pass through EEA1 and Rab7 pos-
itive compartments before its delivery to the lysosome for degradation. Our preliminary data
suggests that the mechanism of FMS downregulation by the constitutive pathway is equiva-
lent to that induced by M-CSF, but dissimilar from that of shedding and RIP degradation.
These results also suggest that the c-KIT and VEGFR2 receptors are also subject to a similar
mechanism of constitutive downregulation and both are also committed to degraded via the
lysosome.
To gain further insight into a possible raison d’eˆtre for the seemingly wasteful process of consti-
tutively degrading the FMS receptor and also possibly the c-KIT and VEGFR2 receptors the
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synthesis rates of FMS was analysed. The rates of FMS synthesis were shown to be constant
irrespective of the receptors mature levels. Inhibition of the receptors degradation by lysosomal
inhibition resulted in an increase in the levels of the mature receptor within cells. This was also
demonstrated for the c-KIT and VEGFR2 receptors. As the synthesis rate of FMS was shown
to be indepedent of its mature levels, we suggest that the constitutive degradation pathway is
part of a homoeostatic mechanism whose function is to buﬀer receptor levels, preventing their
overexpression in a simplistic system where they are synthesised at a constant rate.
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Chapter 1
Introduction
1.1 A history of RTKs
The EGF and NGF growth factors were discovered in the 1960s, prior to the discovery and
realization of the role of their receptors in the 1970s (Levi-Montalcini and Booker, 1960; Cohen,
1962). The essential requirement of growth factors for cells was at this point understood,
however it was unknown how these factors transmitted signals from the extracellular space to
the inside of cells (Schlessinger, 2014). This signal transmission was clearly an essential aspect
of the evolution of multicellular organisms (Hunter, 2014). It was also know by the 1960s and
1970s that cancer cells required less growth factor stimulation for proliferation and that some
cancer cells secreted their own growth factors (Temin, 1966; Temin, 1967).
The receptors for growth factors were initially thought not to possess intrinsic kinase activity
until a series of papers published by Stanley Cohen’s lab demonstrated the phosphorylation of
tyrosine residues on the EGFR upon EGF stimulation (Carpenter et al., 1978; Carpenter et
al., 1979; Ushiro and Cohen, 1980). The intrinsic tyrosine kinase activity of the EGFR was
demonstrated soon after this along with the receptor’s ability to phosphorylate other proteins
(Chinkers and Cohen, 1981; Hunter and Cooper, 1981). Confirmation of their now well-known
intrinsic kinase abilities lead to them being coined receptor tyrosine kinases (RTKs), over a
decade after their initial discovery (Schlessinger, 2014).
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Studies on the transforming potential of proteins from animal tumour viruses such as middle T
antigen and Rous sarcoma virus, lead to the search for similar human oncogenes, leading to the
discovery that the proto-oncogene Src had tyrosine kinase activity (Eckhart et al., 1979; Hunter
and Sefton, 1980). Since this discovery, the family of protein kinases has grown to a total of
566 genes within the human ‘kinome.’ Of these genes 90 are tyrosine kinases (Manning et al.,
2002), and 58 of these are defined as RTKs, which are divided further into 20 subfamilies based
on their structural domains. Some of the genes from these families are likely to have evolved
from recent gene duplications (Lemmon and Schlessinger, 2010; Schlessinger, 2014).
Work on the transforming potential of the animal tumor viruses provided the link between RTK
dysregulation and their potential to cause human disease (Sefton et al., 1980). Since their dis-
covery the RTKs have been shown to play numerous essential roles in development and normal
tissue homeostasis. They also have corresponding roles in pathologies ranging from cancer, dia-
betes and atherosclerosis to bone disorders (Conner and Schmid, 2003; Schlessinger, 2014). The
first protein with tyrosine kinase activity demonstrated to be oncogenic in human cancers was
the BCR-ABL fusion protein resulting from a chromosomal fusion event named the Philadel-
phia chromosome that is found in over 95% of patients with chronic myeloid leukemia (CML)
patients (Hunter, 2007; Schlessinger, 2014). This oncogenic discovery lead to the development
of the small molecule tyrosine kinase inhibitor Imatinib (Gleevec), which was the first tyrosine
kinase inhibitor to receive FDA approval in 2001 for treatment of cancer (Hunter, 2007). The
first inhibitor of an RTK for cancer therapy was the monoclonal antibody, trastuzumab (Her-
ceptin) targeting HER2, clinically in use by 1998 for treatment of HER2-positive breast cancers
(Hunter, 2014). Small molecule inhibitors targeting the tyrosine kinases have been extensively
researched ever since the Imatinib ‘magic bullet’ treatment success. By August 2013 there were
19 tyrosine kinase small molecule inhibitors with FDA approval, 12 of these targeting the RTKs
(Hunter, 2014).
1.1.1 RTK structures
The amino acid sequence of the EGFR was determined in the 1980s enabling better understand-
ing of its function (Ullrich et al., 1984). This lead to the characterization of the EGFR as a type
1 transmembrane receptor containing a large extracellular ligand binding domain consisting of
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approximately 620 amino acids, a single pass transmembrane helix of 23 amino acids, and a large
cytoplasmic domain of approximately 400 amino acids that is highly conserved among RTKs
(the tyrosine kinase domain). This conserved cytoplasmic domain was shown to be flanked by a
less conserved juxtamembrane domain of approximately 30 amino acids, and an approximately
230 amino acid long C-terminal tail (Ullrich et al., 1984; Lemmon and Schlessinger , 2010).
X-ray crystallography structures of the tyrosine kinases provided essential information as to how
these proteins become activated. These crystal structures demonstrated the ability of RTKs to
exist in two distinct structural forms, an inactive version which is more varied in structure and
an active form which displays a markedly similar structure between diﬀerent kinases (Lemmon
and Schlessinger, 2010; Schlessinger, 2014). There are many crystal structures now available
for both active and inactive conformations of the kinases (Nolen et al., 2004; Jura et al., 2011).
Kinase domains are dual-lobed and contain an amino-terminal N-lobe which primarily consists of
β-sheets, and a carboxy-terminal C-lobe which majorly consists of α-helices (Jura et al., 2011).
The active site of all kinases is located between the N- and C-lobes and is often concealed by
an activation loop which has been shown to project into the active site for some receptors, such
as the insulin receptor. This interaction between the active site and activation loop is believed
to stabilize the kinase domain in an inactive conformation (Nolen et al., 2004). Upon ligand
binding the conserved tyrosine residues in the activation loop become phosphorylated in trans.
This modification results in a conformational change of this loop and destabilizes its inhibitory
interactions, causing it to shift away from the activation site. Loss of this occlusion enables
ATP entry into the kinase domain pocket, transfer of the γ-phosphate, and substrate access.
Phosphorylation of these key activation loop tyrosine residues is usually a key step in kinase
activity regulation (Lemmon and Schlessinger, 2010; Jura et al., 2011).
1.1.2 Activation of the RTKs
RTKs are generally activated by the binding of their growth factor ligand(s) to the extracellular
domain of the receptor. RTKs expressed on the cell surface have been subject to conflicting re-
sults as to whether they exist as single receptors, pre-existing dimers or oligomers (Schlessinger,
2014). The EGFR is reported to exist at the cell surface as a monomer, while the insulin receptor
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and insulin-like growth factor-1 receptor (IGF1R) is reported to be pre-dimerised at the cell sur-
face (De Metys, 2008; Lemmon and Schlessinger, 2010). Dimerisation initiation or stabilization
by growth factor binding is believed to result in a conformational change in the receptor, which
is transmitted through the transmembrane alpha helix and through to the intracellular domain.
This results in the loss of inhibition by the inhibitory juxtamembrane domain and C-terminal
tails, restructuring of the kinase domains enabling kinase activation and autophosphorylation,
mediated in trans (Kashles et al., 1991; Honegger et al., 1989; Schlessinger, 2014).
RTKs functions are not limited solely to their role in substrate phosphorylation. They also
play a vital role acting as protein scaﬀolds, recruiting and enabling the interactions of a wide
range of signaling intermediaries including those of the RAS/MAPK, PI3K/Akt and Jak/STAT
signaling pathways (Hunter, 2014; Schlessinger, 2014). RTKs are able to interact with such a
vast range of signaling intermediaries specifically through their phosphorylated tyrosine residues
which have been demonstrated to interact with cytoplasmic proteins containing SH2 (Src ho-
mology region 2) and PTB (phosphotyrosine-binding) domains (Pawson, 2004; Schlessinger and
Lemmon, 2003). The network of proteins recruited to activated RTKs is further expanded by
these SH2 and PTB domain containing proteins which themselves recruit secondary docking
proteins to the expanding complexity of multiprotein complexes. Examples of these include the
recruitment of the Grb and Shp2 proteins to an activated RTK, this results in the recruitment
of further proteins, known as secondary docking proteins such as Gab1 which in turn recruits
and activates PI3-K (Lemmon and Schlessinger, 2010). Activated RTKs and their downstream
signaling pathways have wide ranging roles in multiple cellular processes essential for cell sur-
vival, proliferation, diﬀerentiation, metabolism, development and normal tissue homeostasis
(Schlessinger, 2014).
1.2 Receptor Downregulation: Endocytosis
Overexpression of RTKs results in a hyper-activation state of the cell, whereas underexpression
could render the cell unresponsive to stimuli (Conner and Schmid, 2003; Miaczynska, 2014).
The balance of receptor levels at the cell surface is primarily regulated by endocytosis pathways.
Endocytosis controls receptor levels at the cells surface, regulating the balance between recycling
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and degradation and also influences the compartmentalisation and signalling of activated RTKs
(Miaczynska, 2014).
The first step in receptor downregulation is endocytosis (Mellman and Yarden, 2013). En-
docytosis occurs via a variety of diﬀerent mechanisms that can be broadly categorized into
‘phagocytosis’ and ‘pinocytosis.’ Phagocytosis internalises large particles, which are subse-
quently targeted for degradation. Phagocytosis is primarily carried out by immune cells such as
monocytes, macrophages and neutrophils. Pinocytosis internalises smaller particles and solutes
and occurs in almost all cell types (Aderem and Underhill, 1999; Conner and Schmid, 2003).
Pinocytosis is subdivided into several mechanism of endocytosis. These include; macropinocy-
tosis, clathrin-dependent endocytosis, caveolin-dependent endocytosis and then clathrin- and
caveolin-independent endocytosis (Conner and Schmid, 2003; Le Roy and Wrana, 2005; Mayor
and Pegano, 2007). It is now understood that one receptor can be internalised by multiple
endocytic mechanisms depending on a variety of factors ranging from cell type, ligand con-
centration, multiple ligands for the same receptor, cellular stress factors and even co-receptor
binding (Miaczynska, 2014).
1.2.1 Clathrin-dependent endocytosis
Clathrin-dependent endocytosis occurs in all mammalian cells and is a mechanism of receptor
internalisation essential for the uptake of nutrients such as low density lipoprotein (LDL) and
transferrin (Conner and Schmid, 2003). Recruitment of clathrin triskelia to a region of the
plasma membrane undergoing endocytosis usually occurs via its recruitment by an adapter
protein. The ‘classical’ clathrin adaptor protein is AP-2, a member of the adapter protein
(AP) family (Bonifacino and Lippincott-Schwartz, 2003; Conner and Schmid, 2003). AP-2 is
known to bind to the intracellular domain of RTKs via a D/E-XXX-LL motif (Conner and
Schmid, 2003; Edling et al., 2006; Doherty and McMahon, 2009). Clathrin is then recruited
to this region and induces membrane curvature and invagination of the clathrin-coated pits
which are subsequently pinched of and internalised utilising the GTPase, dynamin (Conner and
Schmid, 2003; Le Roy and Wrana, 2005; Mayor and Pegano, 2007). Clathrin-coated vesicles
have a diameter of approximately 0.2 µm (Mellmand and Yarden, 2013). These internalised
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vesicles shed their clathrin coating shortly after internalisation and fuse with early endosomes
for content sorting (Doherty and McMahon, 2009; Zwang and Yarden, 2009).
1.2.2 Caveolin-dependent endocytosis
Caveolae are small flask-shaped membrane invaginations restricted to cholesterol-rich membrane
microdomains known as lipid-rafts and occur commonly in the cell (Anderson, 1998; Hanson
and Nicols, 2009). The shape and structure of caveolae is regulated by the cholesterol binding
protein, caveolin (Conner and Schmid, 2003; Kirkhan and Parton, 2005; Hanson and Nicols,
2009). There are several isoforms of caveolin, however it is thought caveolin-1 (cav-1) is the
most likely to be primarily involved in caveolin-dependent endocytosis over the other isoforms
due to its universal, high expression pattern and primary cell surface association. Knockout
mice nullizygous for cav-1 display no detectable caveolae, confirming the importance of this
protein for this particular mechanism of endocytosis (Razani et al., 2001; Drab et al., 2001).
Dynamin is recruited to caveolae and like clathrin-coated pits it is required for its ability to
pinch oﬀ the plasma membrane (Henley et al., 1998).
1.2.3 Clathrin- and Caveolin-independent endocytosis
The lesser known mechanism of endocytosis is clathrin- and caveolin-independent which is used
by a number of membrane proteins including the IL-2R, cholera toxin, ricin, MHC I and II
and other GPI-anchored proteins (Kirkhan and Parton, 2005; Hanson and Nicols, 2009). The
mechanism of this endocytosis pathway remains largely unknown as proteins undergoing it are
solely shown to be independent of the other two pathways (Hanson and Nicols, 2009). The IL-2R
is known to be endocytosed in a clathrin- and caveolin independent manner, but is dependent
on dynamin (Kirkhan and Parton, 2005; Mayor and Pagano, 2007).
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1.3 Receptor intracellular traﬃcking
Endocytosed vesicles generally fuse with other small vesicles and tubules, collectively known
as early endosomes. Early endosomal fusion is mediated by the phosphoinositide-3-phosphate
binding protein, early endosomal antigen 1 (EEA1) and Rab5 (Zwang and Yarden, 2009). These
vesicles are mildly acidic with a pH of between 6.0 and 6.8. This lowering in pH frequently results
in the dissociation of ligands from their receptors. The dissociated ligands get transported from
early endosomes to late endosomes and degraded via the lysosome. This dissociation and
degradation of the ligand was first demonstrated with iodinated EGF which dissociates from
its receptor in vesicles, is routed through endosomal compartments and subsequently degraded
by the proteasome (Schaudies et al., 1987).
Receptors subsequently have two options, they can either enter ‘recycling endosomes’ which
are positive for Rab4 and Rab11 and recycle back to the cell surface after ligand dissociation
(Le Roy and Wrana, 2005; Zwang and Yarden, 2009). Alternatively the inactive receptors
follow their ligands fate and are committed to lysosomal degradation. Whether or not an
activated RTK is able to undergo recycling instead of degradation is believed to be dependent
on ligand:receptor dissociation kinetics under acidic conditions. The best known example of
this is exhibited by the two diﬀerent EGFR ligands, EGF and TGF-α. Upon EGF binding the
receptor is degraded, while TGF-α binding induces recycling (Decker, 1990). This has been
attributed to the diﬀerences induced by pH changes in the binding aﬃnities of the two ligands,
the EGF:EGFR complex remains stable under acidification of endosomes, therefore committing
the receptor to degradation, while TGF-α dissociates from the EGFR, leaving it free to recycle
(Ebner and Derynck, 1991; French et al., 1995).
Endosomal maturation from early to late endosomes to multi-vesicular bodies (MVBs) is ac-
companied by the initial loss of EEA1 and Rab5 association after early endosomes, and Rab7
association at the late endosomal stage. Endosomal fusion events result in the progression
through the endosomal traﬃcking pathway deeper into the cell until the lysosome is reached in
the perinuclear region (Sorkin and Goh, 2009).
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1.4 The lysosome
The small granular enzyme containing organelles were first characterised during work carried
out in the early 1950s. They were coined ‘lysosomes’ by the de Duve lab in 1955 using the newly
available cellular fractionation and sucrose gradient technology (see Figure 1.1 for an electron
micrograph image of purified lysosomes) developed and refined by Albert Claude (1946) at
the Rockerfeller institute. The enzymatic contents of lysosomes were identified in what was
believed to be a pure mitochondrial fraction until de Duve’s group refined the fractionation
technology further, separating the heavier mitochondrial fraction from the lighter fraction of
distinct organelles containing acid phosphatases (Appelmans et al., 1954).
Figure 1.1: Lysosomal extract isolated from rat liver at a magnification of x18,400. Taken from
Baudhuin et al., 1965.
Lysosomes constitute between 1 and 15% of the total cellular volume and protein content
of mammalian cells (Dice, 2000). These organelles contain many hydrolases responsible for
digesting proteins into small peptides or free amino acids. Lysosomes contain a range of proteins
that can be classed into 4 major enzymatic groups; proteases and peptidases (including serine,
cysteine, aspartic and metalloproteinases) , nucleases, lipases and glycosidases (Barratt, 1992;
de Duve, 2005). Other proteins found in lysosomes include vacuolar ATPases (V-ATPases),
amino acid transporters and receptors such as LAMP1 and 2 (Dice, 2000).
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The lysosomal pH is estimated to be approximately 5.2-5.6 in fibroblasts, achieved by ATP-
dependent proton pumps (Yamashiro et al., 1983). This pH has been reported to be lower inside
macrophage lysosomes at between 4.7-4.8 and recorded as being able to transiently drop to as
low as 4.5 (Ohkuma and Poole, 1978). This pH is optimal for the full proteolytic activity of
many of the enzymes contained within lysosomes. This acidic environment can be neutralised
experimentally by addition of weak bases such as choloroquine and methylamine to cells.
Recycling-associated regions of the para-Golgi network and endocytic vesicles have a reported
pH of 5.4 and 6.4, respectively (Yamashiro et al., 1984). This weakly acidic pH is implicated in
enabling the dissociation of bound receptor:ligand complexes after their endocytosis and fusion
with vesicles. Ligands that are dissociated from their receptors at an acidic pH enable receptors
to recycle back to the cell surface (Brown et al., 1983). Many receptors have been shown to
dissociate from their neutral-pH bound ligands at a pH of below 6, this can be disrupted by weak
bases such as methylamine resulting in a reduction in surface receptor levels (Gonzalez-Noriega
et al., 1980).
1.5 Matrix metalloproteases
The metzincin superfamily of proteases includes the matrix metalloproteinases (MMPs) and the
a disintegrin and metalloproteinases (ADAMs) (Murphy, 2009).
Membrane proteolysis events are generally categorised into two diﬀerent types of events, known
as ectodomain shedding (Edwards et al., 2008; Murphy, 2009) and regulated intramembrane
proteolysis (RIP). Shedding is defined as the cleavage event that leads to the release of the
target proteins extracellular domain (ECD) into the extracellular matrix (ECM).
1.5.1 ADAM family members
The ADAM family of metalloproteinases were first discovered as sperm-associated proteins
(Blobel et al., 1992). There are 21 diﬀerent ADAM family member genes coded for in humans,
however only 13 of these are functional proteases (Edwards et al., 2008; Murphy, 2009). They
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are known to be involved in development, fertilisation, tissue homeostasis and conversely also
in the progression of multiple diseases including cardiovascular disease, inflammation, asthma,
Alzheimer’s disease and cancer (Murphy, 2008).
The catalytically active ADAMs are involved in the cleavage within the extracellular juxtamem-
brane domains of its protein substrates within close proximity of the plasma membrane (Caescu
et al., 2009; Murphy, 2008). The shedding of pro-forms of various cytokines and ligands as
soluble proteins is known to activate a range of signalling events. The two best-characterised
ADAM family members are ADAM17 (also known as TNF-α converting enzyme, TACE) and
ADAM10. ADAM17 is known to cleave an extremely wide range of substrates however its
best known targets are TNF-α (Black et al., 1997) and the EGFR family ligands, which it is
able to release from their membrane tethers thereby activating signalling via the EGFR family
members (Sunnarborg et al., 20002; Higashiyama et al., 2011).
ADAM10 has a less diverse list of substrates but is best known for its cleavage of the Notch
receptor. Cleavage of Notch by ADAM10, enables the remaining receptor to be subject to a
second cleavage step known as regulated membrane proteolysis (RIP) carried out by the γ-
secretase complex (De Strooper et al., 1999). This enables release of the intracellular domain
of Notch from the membrane where it subsequently translocates to the nucleus and activates
transcription of its target genes (De Strooper et al., 1999; Groot and Vooijs, 2012). Many other
membrane proteins subject to shedding have also been demonstrated as being subject to RIP,
frequently mediated by the γ-secretase complex. The ADAM family of proteases due to their
multiple targets and wide regulatory roles are key players in development and homeostasis.
They therefore have correspondingly been shown to be deregulated in multiple human diseased
states from inflammatory disorders to cancer (Seals and Courtneidge, 2003; Kawaguchi and
Hearing, 2011; Edwards et al., 2008).
1.5.2 ADAM17
ADAM17 is the protease responsible for cleavage of a wide range of substrates including TNF-
α, EGF ligands, IL-6, L-selectin, TNFR2, FMS, transmembrane CSF-1, c-Met, Erbb4 (JMa
isoform), amyloid precursor protein (APP) and TrkA (Peschon et al., 1998; Ni et al., 2001;
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Scheller et al., 2011; Mullberg et al., 1995; Pruessmeyer and Ludwig, 2009; Chalaris et al.,
2010). Despite the wide range of substrates no consensus motif has been discovered for the
enzyme to date, despite extensive analysis (Caescu et al., 2009).
The embryonic lethality of the ADAM17 homozygous knockout mouse model demonstrates
the importance of this protease in development (Peschon et al., 1998; Jackson et al., 2003;
Sunnarborg et al., 2002). Due to the proteases wide expression and substrate range it is unsur-
prisingly involved in many diﬀerent physiological processes; roles which correspondingly have
been linked to multiple human diseased states including, rheumatoid arthritis, diabetes, cancer
and Alzheimer’s disease (Murphy, 2008; Arribas and Esselens, 2009; Gooz, 2010).
1.5.3 iRhoms
The inactive rhomboid proteins 1 and 2 (iRhom1 and 2) were recently demonstrated to have
critical and overlapping functions in the maturation of ADAM17. IRhom1 is widely expressed
in most tissue types except for macrophages; iRhom2 displays a more restricted expression
pattern, primarily to immune cells (Su et al., 2004). Macrophages were shown to upregulate
iRhom2 in response to LPS treatment (Adrian et al., 2012). The authors therefore decided to
examine the role of iRhom2 using knockout mice. Knockout mice for iRhom2 displayed almost
abolished TNF-α production in response to LPS in contrast to wild-type mice, this was shown
to be due to a lack of ADAM17 activity in these cells. IRhom2 was demonstrated to directly
bind to ADAM17 through extensive co-immunoprecipitation studies and be a rate-limiting step
in ADAM17 furin-dependent activation, required for its exit from the ER (Adrian et al., 2012;
Mcllwain et al., 2012; Siggs et al., 2012).
iRhom2, was subsequently shown, in addition to its role in ADAM17 maturation, to also be
able to regulate some of the enzyme’s substrates, such as a selection of the cell surface bound
EGFR ligands and that of the c-KIT receptor ligand. The shedding of HB-EGF and Kit ligand
2 was demonstrated to be abolished in iRhom2 knockout mEFs, however TGFα release was
unaﬀected by the knockout (Maretzky et al., 2013). This research strongly suggests a role for
additional proteins in the regulation of ADAM17 substrates. This partially explains how the
protease has such a diverse range of substrates despite the lack of a consensus motif for their
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recognition.
1.5.4 RIP
Shedding of the extracellular portion of a transmembrane protein can in some cases lead to a
second cleavage event, known as regulated intramembrane proteolysis (RIP), a highly conserved
process in archaea, bacteria and eukaryotes (Krolewski, 2005). RIP is frequently carried out
by a multi-subunit enzyme known as the γ-secretase complex (Landman and Kim, 2004). The
γ-secretase complex is a member of the presenilin family of aspartyl proteases. It has no appar-
ent consensus motif for its transmembrane targets, however a common feature is its frequent
requirement for a primary cleavage event (i.e. by a member of the ADAM family) to enable its
substrate recognition and cleavage (Fortini et al., 2002; Hass et al., 2009; Landman and Kim,
2004).
1.6 FMS
Colony stimulating factor-1 (CSF-1 or M-CSF), was discovered and named according to its
ability to stimulate the growth and diﬀerentiation of macrophage colonies (Stanley et al., 1978).
A putative receptor was subsequently identified that could bind to iodinated CSF-1 and that was
only expressed by cells responsive to CSF-1 (Guilbert and Stanley, 1980). The CSF-1 receptor
(also known as the FMS receptor or M-CSFR) was subsequently found to be identical to the
product of the v-fms oncogene which was originally isolated from a feline sarcoma (Sherr et al.,
1985). FMS is the protein product of the c-fms proto-oncogene (Sherr et al., 1985). Shortly
after its cloning, FMS was shown to be a member of the class III family of RTKs (Coussens et
al., 1986), possessing intrinsic tyrosine kinase activity (Yeung et al., 1987). It is a close relative
of the PDGFRα, PDGFRβ, c-KIT and FLT3 receptors which are all defined by their possession
of 5 immunoglobulin-like domains in their extracellular domain and possession of a two-lobed
kinase domain which is interrupted by a short kinase insert loop [Ullrich and Schlessinger, 1990,
Blume-Jensen and Hunter, 2001; Lemmon and Schlessinger, 2010].
FMS is a highly glycosylated membrane protein that can be readily detected as an immature
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form of approximately 150 kDa, and a more extensively glycosylated mature protein with a
molecular weight of 175 kDa [Rettenmier et al., 1985]. The size of the mature receptor can vary
slightly between cell lines depending on the extent of post-translational glycosylation occurring.
FMS is comprised of an extracellular domain consisting of 498 amino acids, a transmembrane
domain, an intracellular juxtamembrane domain and the intracellular tyrosine kinase domain,
which is a two-lobed structure consisting of 398 amino acids, interrupted by a kinase insert
loop of 73 amino acids. FMS has a tail region of approximately 50 amino acids (see Figure 2.1;
Coussens et al., 1986; Rothwell and Rohrschneider, 1987; Hampe et al., 1989).
1.6.1 FMS Expression
The FMS receptor is expressed primarily in cells of the monocyte lineage (Byrne, 1981) and by
some cells of the female reproductive tract (Wei et al., 2010). It is expressed at low levels in
hematopoietic stem cells (Sarrazin et al., 2009) and this expression increases by approximately
10 fold upon diﬀerentiation to monocytes (Bartlemez et al., 1989), and reaches maximal ex-
pression levels in macrophages (Guilbert and Stanley, 1980; Byrne et al., 1981), osteoclasts,
dendritic cells (MacDonald et al., 2005), microglia (Nandi et al., 2012) and Paneth cells (Huynh
et al., 2009). The importance of FMS is dependent on the host cell being analysed (Hamilton,
1997). In macrophages, their diﬀerentiation, proliferation, survival, migration and various other
cell specific functions such as bacterial phagocytosis are largely regulated by FMS receptor sig-
naling (Sherr, 1990; Pixley and Stanley, 2004; Chitu and Stanley, 2006; Stanley and Chitu,
2014).
Specificity and maximal expression of FMS in the monocyte/macrophage lineage is achieved
by two mechanisms. One involves its purine rich promoter sequence, and the macrophage
transcription factor, PU.1 [Zhang et al., 1994; Inaba et al., 1996] and results in chromatin
remodeling of the promoter (Follows et al., 2005; Krysinska et al., 2007). Maximal expression
of FMS in monocytes and macrophages requires a 330 bp highly conserved enhancer element
known as the FMS-intronic regulatory element (FIRE). Extensive chromatin remodeling around
the FIRE sequence and assembly of the transcription factor assembly complex (PU.1, Runx1
and C/EBP binding) to this region is the second step involved in FMS expression regulation
(Himes et al., 2001; Tagoh et al., 2002; Follows et al., 2005; Bonifer and Hume, 2008; Stanley and
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Chitu, 2014). These cell type specific modifications ensure that specific cells of the hematopoietic
lineage are maximally responsive to FMS ligands and signaling. In contrast to cells with lower
FMS expression, which frequently require synergism between the FMS ligand stimulation and
other growth factors signalling such as that elicited by the addition of ligands such as IL-3 and
SCF to enable downstream signalling pathway activation (Baker et al., 1994).
1.6.2 FMS ligands
FMS exerts its range of eﬀects upon cells through the binding of one of its two known ligands,
the well-established M-CSF and the recently discovered IL-34 (Lin et al., 2008). FMS is the
only known RTK that is activated by two ligands possessing no amino acid homology (Stanley
and Chitu, 2014). Both growth factors bind to distinct regions of the ligand binding domains of
extracellular region of the FMS receptor (Liu et al, 2012; Ma et al., 2012; Felix et al., 2013). The
D2 and D3 immunoglobulin-like (Ig-like) domains in the extracellular portion of the receptor
are responsible for ligand binding. The two ligands display similar, but not identical biological
activity and signalling capabilities [Chihara et al., 2010, Wei et al., 2010; Wang and Colonna,
2014]. The main diﬀerence between the two ligands is their distinct spatiotemporal expression.
IL-34 is expressed in the central nervous system, while M-CSF is more broadly expressed and
is readily detectable in the circulation at concentrations around 10 ng/ml in healthy humans
(Hume and MacDonald, 2012). This diﬀerential expression pattern indicates the likelihood of
diﬀerent biological functions for the two ligands [Liu et al., 2012, Nandi et al., 2012].
1.6.3 FMS activation and downregulation
Using electron microscopy and small-angle X-ray scattering, FMS was strongly implicated as
existing on the cell surface prior to ligand binding as pre-dimerised (Elegheert et al., 2011).
Both ligands have been shown to bind to the D2 and D3 domains of the extracellular portion of
the receptor (Elegheert et al., 2011). A dimerization domain motif involving residues arginine
383 and glutamic acid 373 which are implicated in forming ionic bonds between two FMS
receptors was determined on the D4 section (see schematic in Figure 1.2). This motif resembles
that found on the closely related c-Kit (Yuzawa et al., 2007) and PDGF receptors (Yang et
33
al., 2008). Upon CSF-1 binding to pre-dimerized FMS, the receptor undergoes a first wave of
tyrosine phosphorylation. During this phosphorylation wave it has been shown to associate with
Grb2/Sos and SFK, Cbl and p85 (the regulatory subunit of PI3K) (Baccarini et al., 1991; Li
and Stanley, 1991; Wang et al., 1996; Wang et al., 1999). The FMS receptor is phosphorylated
on 8 tyrosine residues upon ligand binding (see Figure 1.2 for details) (Stanley and Chitu, 2014).
Association with Cbl leads to the receptors ubiquitination (Lee et al., 1999), and subsequent
internalization where the receptor can be detected in multivesicular bodies prior to its routing
to the lysosome for degradation (Guilbert and Stanley, 1986; Lee et al., 1999). The extensive
signaling molecules and pathways activated by FMS can be observed in Figure 1.3.
CSF-1 activation of FMS induces protein synthesis induction of FMS-specific gene targets which
can be detected as early as 15 minutes after stimulation and plateaus after 2 hours (Tushinski
and Stanley, 1983). Increased motility and chemotaxis of cells following CSF-1 stimulation (see
Figure 1.3 for details) occurs after the increased protein synthesis is detectable (Pixley et al.,
2001; Chitu et al., 2005). Macrophages can be determined as entering S phase of the cell cycle
approximately 12 hours post stimulation, this is associated with a dose-dependent increase in
protein synthesis rate (Tushinski and Stanley, 1983; Tushinski and Stanley, 1985).
1.6.4 GW2580
Kinase inhibitors are highly useful tools in research and as therapeutics. However, achieving
specificity has proven challenging for most kinases. Kinase inhibitors typically act as ATP-
competitors binding to a receptor’s ATP-pocket. This generally makes them highly promis-
cuous especially within closely related targets (Burns and Wilks, 2011). The modulation by
FMS signalling in macrophages is thought to have applications in inflammatory disease, cancer,
autoimmunity and bone neurological disease [Hume and Macdonald, 2012]. The FMS recep-
tor is now considered an attractive drug target. Inhibition of FMS may enable us to further
understand its role in disease and to develop more eﬀective therapeutics [Burns and Wilks,
2011].
A highly specific kinase inhibitor against the FMS kinase was recently developed (Conway et
al., 2005). It is a competitive ATP inhibitor, which was shown to display no activity towards 26
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kinases tested initially (Conway et al., 2005) and its specificity was determined in comparison
to 186 kinases tested in a later study (Conway et al., 2008). GW2580 was shown to inhibit the
growth of cells dependent on FMS signaling in comparison to 8 other cell types tested (Conway
et al., 2005).
At its maximal concentration of 1 µM it inhibited bone degradation in human osteoclasts
and monocyte growth in vitro (Conway et al., 2005). GW2580 was also shown to be orally
bioavailable making it an important breakthrough in kinase inhibitor research and potentially
therapeutically. This was tested in arthritis studies, showing protective eﬀects on joint integrity
in rat arthritis models, while having minimal eﬀects on healthy rats (Conway et al., 2008). Its
potency and selectivity has proven a unique tool for research carried out since its development,
enabling a full analysis of the eﬀects of FMS signaling with minimal if any side eﬀects other
than the intended.
FMS and shedding/RIP
The FMS receptor was first shown to be downregulated by LPS in the 1980s (Chen et al.,
1983; Sester et al., 1999), where it was demonstrated to become unresponsive to CSF-1 after
LPS stimulation (Guilbert and Stanley, 1984). CSF-1 binding to its receptor was also shown
to be inhibited by phorbol ester treatment (Chen et al,. 1983). Both IL-2 (Sbarba et al.,
1996a) and IL-4 (Sbarba et al., 1996b) stimulation were also demonstrated to downregulate
FMS by an unknown mechanism at this stage. Partial aspects of the mechanism began to
emerge later. LPS-induced downregulation was shown to be dependent on PKC (Baccarini et
al., 1992) and PMA-dependent downregulation on ERK (Sester et al., 1999; Glenn and van
der Geer, 2008). ADAM17 was soon after identified as responsible for proteolysis of FMS in
response to macrophage polarisation or TPA stimulation (Rovida et al., 2001; Glenn and van
der Geer, 2008).
Soon after the characterisation of ADAM17 mediated FMS proteolysis, it was discovered that
the receptor was subject to a two-step cleavage process, the first mediated by ADAM17 and the
second by the γ-secretase complex (see Figure 1.4 for a schematic of FMS cleavage and Figure
1.2 for cleavage site details; Wilhelmsen and van der Geer, 2004; Glenn and van der Geer, 2008).
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The degradation routes followed by CSF-1 stimulation and shedding induction by TPA were
characterised as distinct, with CSF-1 induced degradation inducing the lysosomal degradation
of FMS, and shedding/RIP resulting in the ubiquitination and subsequent rapid proteasomal
degradation of the released ICD (see Figure 1.4 for a schematic of the two pathways of FMS
downregulation) (Glenn and van der Geer, 2007).
The cleavage site for both ADAM17 and the γ-secretase complex remained unknown until
recently. The ADAM17 cleavage site was determined to be between the glutamic acid at residue
503 and serine at 504. The γ-secretase complex cleavage occurs within the transmembrane
domain between leucines 532 and 533 (see Figure 1.2 for schematic) (Vahidi et al., 2014).
FMS receptor knockout mice
The importance of the FMS receptor in expressing cells can be demonstrated by knockout mice
studies. Mice with a homozygous deletion of the gene encoding the M-CSF protein product
called CSF1op/op mice display a severe phenotype. They suﬀer from congenital osteopetrosis
are toothless, have a reduced body mass, size and growth rate, have extensive skeletal formation
defects and are deficient in tissue macrophages (Wiktor-Jedrzejczak et al., 1990). Additionally
they display defects in fertility (male and female), neural development, dermis and synovial
membranes (Ryan et al., 2001; Dai et al., 2002). Mice with inactivating mutations of the c-fms
gene, CSF-1R-/- displayed a similar but more severe phenotype, with worse osteopetrosis than
the CSF-1 knockout. Both nullizygous knockouts are postnatally lethal (Dai et al., 2002). This
more severe phenotype of the CSF-1R-/- knockout in comparison to the CSF1op/op knockout
has since been attributed to the overlapping functions of M-CSF and IL-34.
FMS and Disease
FMS signaling promotes the diﬀerentiation, survival and proliferation (among other functions)
of expressing cells by regulating the tyrosine phosphorylation, activation and expression of a
diverse range of proteins (Hume, 2006; Stanley and Chitu, 2014). It is therefore also a potential
candidate for dysregulation in human disease (Pixley and Stanley, 2004; Hume, 2006; Chitu
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and Stanley, 2014).
Osteoclasts and disease
Bone is a highly dynamic structure that undergoes constant remodelling through a balance
of the actions of bone reabsorbing osteoclasts and bone synthesizing osteoblasts (Boyle et al.,
2003). Osteoclasts are diﬀerentiated by the growth factor combination of RANKL and M-CSF
in vitro. The majority of adult skeletal diseases are due to excessive osteoclast activity, resulting
in a shift in the balance between bone synthesis and re-sorption favouring the latter, ending
in a decrease in bone density (Rodan and Martin, 2000). These diseases include osteoporosis,
rheumatoid arthritis, periodontal disease, multiple myeloma and metastatic cancer (Boyle et
al., 2003). Inhibition of FMS signalling in these diseases may help reduce osteoclast numbers,
therefore restoring the upset balance of bone remodelling. Further to this theory CSF-1 is
known to be upregulated in several human cancers and also rheumatoid arthritis (Pollard,
2004; Chitu and Stanley, 2006) emphasising a possible therapeutic role for FMS inhibitors in
reducing osteoclast activity.
Microglia
Microglia are the macrophage population resident in the central nervous system (Chitu and
Stanley, 2006). CSF-1 is a key regulator of inflammation in the brain and it is upregulated in
many diseased states including HIV-1 encephalitis, Alzheimer’s disease and brain tumours (Imai
and Kohsaka, 2002). However the extent of contribution of FMS signalling to the progression
of these diseases is not well understood. Research using tools such as GW2580 could greatly
aid elucidation of the extent of FMS involvement in these pathologies.
Macrophages
CSF-1 levels are elevated in chronic inflammatory diseases such as lupus and arthritis (Chitu
and Stanley, 2006). CSF-1 production by synovial fibroblasts in patients with rheumatoid
arthritis is believed to result in an increase in osteoclast diﬀerentiation and subsequent bone
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destruction (Chitu and Stanley, 2006). Macrophages have also been implicated in instigating
plaque destabilisation in atherosclerosis, this has also been linked to CSF-1:FMS signalling in
cells (Irvine et al., 2009; Shaposhnik et al., 2010; Schrijvers et al., 2007). CSF-1 deficiency or
inhibition of FMS signalling using a kinase inhibitor such as GW2580 ablated plaque formation
and destabilisation in mouse models (Chitu and Stanley, 2006; Irvine et al., 2009; Schrijvers et
al., 2007).
FMS mutations and transforming potential
The role of FMS as a proto-oncogene became clear upon its sequencing which showed its high
homology to the known oncogene, v-fms (Heisterkamp et al., 1983; Rettenmier et al., 1985).
The v-fms oncogene is a product of a truncation mutation of the C-terminus of the c-fms gene
with two additional transforming point mutations in the extracellular domain of the receptor
(Woolford et al., 1988). These extracellular point mutations were mapped to the D4 domain
known to contain the dimerization interface of the receptor (Elegheert et al., 2011; Ma et al.,
2012). An activating mutation of FMS was recently discovered in human acute megakaryoblastic
leukemia (AML). A chromosomal translocation event between a gene for the RNA binding motif
6 (RBM6) and c-fms was shown to occur in AML, resulting in the production of the protein
fusion product, RBM6-CSF-1R. This fusion protein induces the constitutive activation of the
FMS kinase domain (Gu et al., 2007).
Hereditary diﬀuse leukoencephalopathy with spheroids (HDLS) is another example of a recently
identified disease with mutations in the c-fms gene in several patients from multiple families.
The mutations map to the kinase domain of FMS resulting in the receptors inability to sustain
signaling in the presence of CSF-1, indicating that the c-fms mutations are inactivating (Pridans
et al., 2013). Similar inactivating mutations were also found in several patients with pigmented
orthochromatic leukodystrophy (POLD) (Nicolson et al., 2013). Loss of both c-fms alleles was
also reported in patients with myelodisplasia, an event potentially implicated as enabling the
pathogenesis of myeloid leukemia in these patients (Boultwood et al., 1991).
A protein encoded for by the Epstein-Barr virus produces a secreted hexameric protein product
that binds to the FMS ligand, M-CSF with high aﬃnity. This inhibits the binding of M-CSF to
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FMS, therefore downregulating FMS signalling by reducing the available ligand concentration
(Strockbine et al., 1998; Elegheert et al., 2012). This has been speculated as an immunosup-
pressive adaptation of the virus aiding its avoidance of immune detection by neutralizing FMS
signalling (Stanley and Chitu, 2014). Conversely a chromosomal translocation resulting in over-
expression of M-CSF in cells of the synovial lining has been implicated as being a contributing
factor to the pathogenesis of disease in patients suﬀering from diﬀuse-type giant cell tumours
(dt-GCT). The disease is characterised by mass infiltration of FMS expressing cells into the
synovial lining. These cells form the bulk of the tumour mass (West et al., 2006; Cupp et al.,
2007).
Cancer and TAMS
The tumour microenvironment is well established as playing a major role in enabling tumorige-
nesis and contributing to the many diﬀerent cancer hallmarks (Hanahan and Weinberg, 2011).
The link between cancer development and inflammation is also well known. Tumour associated
macrophages (TAMs) are the primary link between these two diseased states (Allavena et al.,
2008). Several inflammatory diseases such as inflammatory bowl disease increase the risk of can-
cer development (Mantovani et al., 2008; Mantovani, 2009). It is now recognised that at least
15% of cancers worldwide can be determined as having infectious origins (Kuper et al., 2000).
Pre-neoplastic lesions and tumours are well known as frequently being densely populated with
immune cells (Coussens et al., 2002; Hanahan and Weinberg, 2011). Clinical data has shown a
negative correlation, particularly for breast, prostate, ovarian and cervical, between the number
of infiltrating TAMs in solid tumours and patient prognosis (Pollard, 2004; DeNardo et al.,
2011; Kurahara et al., 2011).
Macrophages have long been associated with aiding the progression of solid tumours and are
thought to promote angiogenesis and enable metastasis (Pollard, 2004). This wide range of
eﬀects is controlled by TAMs secretion of growth, survival and proangiogenic factors and extra-
cellular matrix remodelling proteases (Pollard, 2004; Mantovani, 2009; Hanahan and Weinberg,
2011).
The paracrine signalling between macrophages and tumour cells is also well characterised with
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macrophages frequently secreting growth factors such as EGF, and tumour cells in return se-
creting CSF-1 (Hanahan and Weinberg, 2011). The upregulation of CSF-1 in the circulation
of cancer patients is a well-recognised biomarker for some types of cancer. A significant in-
crease in circulating CSF-1 was found in the blood of patients with malignant hematologic
disorders (Janowska-Wieczorek, 1991) and elevated levels in the serum and ascites of patients
with epithelial ovarian cancer is also associated with a poor prognosis (Chambers et al., 1997).
1.6.5 Protein Degradation
There have been numerous theories about what regulates whether a protein is degraded via
the proteasome or lysosome. These have ranged from ubiquitinated proteins being primarily
degraded by the proteasome which is now disputed (Korolchuk et al., 2010; Qiao and Zhang,
2009) to extensive cross-talk and plasticity between the two pathways (van Kerkhof et al., 2001;
Korolchuk et al., 2010). A newer theory reviewed by Rothman (2010) describes a belief that
cytoplasmic and nuclear proteins are degraded via the proteasome, and other proteins contained
in larger structures such as the cell membrane are degraded via the lysosome. Lysosomal degra-
dation is widely believed to be a slower mechanism of degradation than proteasomal degradation
due to its rate-limiting step being the slower membrane fusion (Rothman, 2010).
Interestingly, first order kinetics of proteins degradation have previously been demonstrated
to be a random process, dependent upon protein concentration as newly synthesized proteins
have been shown as just as likely to be degraded than older ones (Borsook and Keighley, 1934;
Goldberg and Dice, 1974).
1.6.6 Constitutive receptor degradation
Most proteins within the cell have been reported to be extremely stable in the absence of stimula-
tion, with average half-lives estimated at above 46 hours (Schwanha¨usser et al., 2011). However
a number of receptors are known to be constitutively endocytosed and degraded, displaying
shorter than average half-lives. The transferrin and low-density lipoprotein (LDL) receptors are
known to be constitutively endocytosed, a process associated with receptor recycling, however
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these are not associated with degradation but simply receptor recycling (Conner and Schmid,
2003; Mousavi et al., 2004). The receptors that display short half-lives in the absence of obvious
stimulation or activation include; the VEGFR2 receptor with a reported half-life of 70 minutes
(Calera et al., 2004); the FMS receptor displaying a reported half-life of 2-3 hours (Rettenmier
et al., 1987; Carlberg et al., 1991); c-Met has also been demonstrated as having a half-life of
approximately 5 hours (Giordano et al., 1989); the FGFR3 receptor with a half-life slightly
over 2 hours (Cho et al., 2004); the IL-6R which was demonstrated to have a half-life of 2-3
hours in the absence or presence of IL-6 (Gerhartz et al., 1994); the TrkA receptor half-life was
reported as 138 minutes in the absence of its ligand, nerve growth factor which shortened its
half-life to 86 minutes (Jullien et al., 2002) and the c-Kit receptor which exhibited a half-life of
slightly under 2 hours by S35 methionine pulse-chase labelling in a mast cell line and primary
bone marrow derived mast cells (Yee et al., 1993).
Although the constitutive degradation of receptors has been widely reported (see above) there
has been little discussion of these observations and as far as we know a possible biological role
for this phenomenon has not been proposed. My laboratory has also observed that FMS is
constitutively degraded when expressed in Rat-2 fibroblasts (Morley et al., 1999) and has been
investigating the possible implications of this observation (Russell, PhD Thesis).
1.7 Project Aims
1. To confirm that constitutive degradation in the absence of shedding and ligand stimulation
occurs in endogenously expressing FMS cells.
2. Elucidate the mechanism behind the constitutive degradation of the FMS receptor.
3. Identify other potential receptors that may be subject to constitutive degradation.
4. Explore the biological role of the constitutive degradation pathway.
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Chapter 2
Materials and Methods
2.1 Cell Culture
2.1.1 Cell lines
All cell lines used were kindly provided by Dr Nick Dibb. Cells used were grown in the stated
media, supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 100 units penicillin
and 100 µg/ml streptomycin (P/S/G), unless otherwise stated. DMEM media containing full
supplement is referred to as D10, and RPMI as R10. Rat2 fibroblasts were maintained in D10
at 37◦C with 10% C02 . Rat2 fibroblasts had been stabily transfected with the c-FMS plasmid
or mutant receptors as previously described in Uden et al., (1999). Raw 264.7 macrophage-
like cells, Hek and Hela cells were all cultured in D10 at 37◦C with 5% C02 . Raw 264.7
cells were not cultured past passage 40. MO7E cells were maintained at 37◦C, 5% CO2 in
RPM1, supplemented with 20% FCS, P/S/G, 40 ng/ml GM-CSF. After freeze-thawing cells
were additionally supplemented with 10 ng/ml SCF until recovered and SCF was subsequently
withdrawn.
All FCS used was heat inactivated by incubation at 56◦C for 30 minutes. FCS was screened to
contain no bovine CSF-1 by its inability to support FDCP1 cells expressing the c-fms plasmid,
which are dependent on FMS signalling for their survival.
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Adherent cell lines (Rat2, Raw 264.7, Hek and Hela cells) were grown in T75 vented flasks,
and passaged twice weekly. Cells were washed once in PBS, and incubated in 2-5 mls of 0.25%
trypsin for 2-5 minutes or until cells were in suspension. Cells were then diluted to 10 mls with
media and pelleted at 1000 rpm for 3 minutes to remove the trypsin and plated to the desired
density. Suspension MO7Es cells were grown in 6 well trays and passages twice weekly. Cells
were split by transferring a small amount of cell suspension to a fresh well at the desired density.
2.1.2 Primary Cells
Bone marrow macrophages
Hind legs from mice back legs were kindly donated by Dr Mhairi Laird, Dr Anil Chandrashekran,
Jossie Mora, Dr Shoma Nakagawa and Reece Williams. Tissue was cut away from the tibia and
femur (if possible) bones as extensively as possible to remove any contaminating cells from the
fat and muscle tissues. Bones were then cut at the foot and kneecap joints to create open
ends where the bone marrow was flushed out using several mls of media with a 27G needle and
1 ml syringe. Bone marrow extracts were subsequently passed through a 40 µm nylon filter
and plated to the desired density (usually 1 x 6 well plate per 2 legs). Cells were allowed to
diﬀerentiate for 48-72 hours before undiﬀerentiated cells were removed by media aspiration, 2
x PBS washes and re-incubation in fresh media. Cells were grown in D10 supplemented with 5
x 103 U/ml hM-CSF, and maintained at 37◦C with 5% C02. Media was changed twice weekly
and bone marrow macrophages (BMM) cells were not passaged passed P1. BMM cells were
withdrawn from M-CSF for up to 24 hours for all FMS experiments.
HUVEC
Human umbilical vein endothelial cells (HUVEC) were kindly donated from Professor Justin
Mason. Cells were maintained in D10 supplemented with 30 µg/ml endothelial cell growth
supplement and 100 U/ml Heparin at 37◦C with 5% CO2 . Cells were not used past passage
6. To split, cells were washed in PBS, incubated with 2 mls 0.25% trypsin for 2-5 minutes.
Trypsin was neutralized by addition of media to a total volume of 10 mls, and cells pelleted by
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centrifugation at 1000 rpm for 3 minutes. Cells were then plated to the desired density.
Osteoclastogenesis
Bone marrow was extracted from mouse tibia as described above. Bone marrow was plated onto
13 mm2 glass coverslips (VWR) in 24 well plates and incubated with 5 x 103 U/ml M-CSF and
40 ng/ml RANKL. Media was changed every 2-3 days for 2-3 weeks. Osteoclasts were defined
as the large multinucleated cells with 5 or more nuclei stained using DAPI.
2.1.3 Growth factors
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) (62-10-
207), recombinant human stem cell factor (rhSCF) (62-64-206), recombinant murine recep-
tor activator of nuclear factor kappa-B ligand (rmRANKL) (66-35-206), recombinant human
Interleukin-4 (rhIL-4) (62-30-207), recombinant human epidermal growth factor receptor (rhEGF)
(62-00-250) and recombinant human vascular growth factor-A (rhVEGF-A) (156) (62-74-206)
were all obtained from First Link (UK) Ltd. Growth factors were diluted to a stock concentra-
tion between 10-40 µg/ml in 0.05% BSA/PBS (0.2 µm filtered). Human M-CSF was obtained
from Chiron and diluted to a final stock concentration of 5 x 105 U/ml in 0.05% BSA/PBS (0.2
µm filtered).
2.1.4 Freezing Cell Lines
Adherent cells were grown to confluence in T75 flasks, suspension cells were grown to confluence
in 6 well plates. Adherent cells were trypsin-suspended and centrifuged as previously described,
cell pellets were re-suspended in 2-3 mls of media containing 10% DMSO, 1 ml of cell suspen-
sion in freezing media was transferred into each cryo-vial. Suspension cells were pelleted by
centrifugation as above and re-suspended in media containing 10% DMSO, contents of one well
were transferred into each cryo-vial. Cells were frozen down to -80◦C using freezing apparatus
prior to transfer into liquid nitrogen tanks for long-term storage.
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Table 2.1: Conditions for inhibitors.
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2.2 Western Blotting Analysis
2.2.1 Lysate sample preparation
Media was aspirated upon experiment commencement, cells were washed 2 x in PBS at 4◦C
and any remaining liquid was aspirated. Cells were lysed in the relevant volume of ice cold
RIPA/SDS lysis buﬀer (1% Nonidet P-40 Substitute, 1% Triton X-100, 0.1% SDS, 150 mM
NaCl2 , 10 mM Tris-HCl pH 8.0, 2 mM NaF) with protease inhibitors (1 mM PMSF, 2 µg/ml
aprotinin and 1mM sodium orthovanadate). Lysates were transferred to pre-chilled Eppendorf’s
and centrifuged at 13,000 rpm at 4◦C for 5 minutes. Supernatants were transferred to fresh Ep-
pendorf’s. Lysates were either used immediately or stored at -20◦C until required. Laemmli lysis
buﬀer with 7 M urea (20% glycerol, 2% SDS, 0.1 m Tris-HCl pH 6.8, 10% β-mercaptoethanol,
7 M urea) was added prior to SDS-PAGE.
BCA protein concentration analysis
Protein concentration was assessed using the BCA assay kit (Pierce) according to the manufac-
turer’s instructions. Samples were analysed using a spectrophotometer reading at 562 nm.
2.2.2 SDS-PAGE gel electrophoresis
Proteins were separated by SDS-PAGE electrophoresis using acrylamide gels. The resolving gel
percentage was determined according to protein size; stacking gels were 4% acrylamide (See
Table 2.2 for details and volumes).
Lysates with equal protein contents and 10 µL of the broad range marker (NEB P7709) were
loaded into wells using a Hamilton syringe. Gels were run in a vertical midi electrophoresis
tank (ATTO) in 1 x SDS running buﬀer. Lysates were run into the resolving gel at 60 volts
for approximately 30 minutes. Once samples had entered the resolving gel the voltage was
increased to 120-135 volts and run for approximately 2 hours.
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Table 2.2: SDS-PAGE gel recipes. Volumes of reagents required to make 10 mls of the indicated
resolving and stacking gels. Tris-HCl for resolving and stacking gels has a pH of 8.8 and 6.5
respectively. All volumes listed are in mls.
Gels were transferred onto nitrocellulose membranes (0.2 µm pore size) using a semi-dry transfer
machine. Foam pads, Whatman paper, membrane and gel were briefly pre-soaked in cold
transfer buﬀer (190 mM glycine, 25 mM Tris-hydroxymethyl-aminomethane, 20% methanol).
The stack was then assembled as per the usual method; briefly, a foam pad was covered with
two pieces of filter paper, the membrane was placed on top of this and the gel was arranged over
the membrane with care being taken to avoid air bubbles between the gel and membrane. The
gel was then topped with another two pieces of filter paper and the final foam pad. The stack
was then transferred in the direction of assembly to the semi-dry machine, enabling protein
transfer down and onto the membrane upon current flow through the electrodes. Proteins were
transferred at 300 mAmps and variable voltage (limited to 20 V) for a minimum of 30 and
maximum of 90 minutes (determined by the molecular weight of the protein of interest). Full
marker transfer was checked prior to gel removal in case of ineﬃcient transfer.
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2.2.3 Ponceau
Loading consistency and transfer eﬃciency was measured using ponceau red staining. Newly
transferred membranes were washed 3-4 times for 2-3 minutes in dH2O prior to membrane
staining. Ponceau S red stain (0.2% ponceau S, 5% acetic acid) was added for up to 5 minutes (or
until proteins were visibly stained) with gentle shaking at room temperature. Excess ponceau
stain was washed oﬀ and membranes were sometimes scanned for use as a loading control.
Membranes were then washed in dH2O with gentle shaking at room temperature until ponceau
stain was fully washed oﬀ. Membranes were transferred into 50 ml falcon tubes for subsequent
steps.
2.2.4 Protein Detection
Membranes were blocked for 30-60 minutes at room temperature in 5% non-fat milk or 5% bovine
serum albumin (BSA) both dissolved in 1 X TBS/0.15% Tween 20 (TBS-T). Membranes were
subsequently incubated with 5 mls of the primary antibody diluted in the relevant blocking
buﬀer (see Table 2.3 for details) either overnight at 4◦C or at room temperature for up to 5
hours. Primary antibodies that are reusable (see Table 2.3) were incubated with 0.05% sodium
azide and reused until signal became too weak.
After primary antibody incubation membranes were washed 3 x 5 minutes (3 x 15 minutes for
the C-terminal FMS antibody) at room temperature in TBS-T and incubated in an appropriate
horse radish peroxidase-conjugated secondary antibody in 5% milk/TBS-T. Secondary antibod-
ies were diluted at a 1:5,000-1:10,000 and incubated for 30-60 minutes with membranes at room
temperature. Membranes were then washed 3 x 5 minutes at room temperature and incubated
in ECL reagent (Immobilon chemiluminescent HRP substrate, Millipore, 1ml reagent A: 1 ml
reagent B) for 30-60 seconds at room temperature. Signal detection was subsequently carried
out using blue film and a film developing machine (Kodak).
50
Table 2.3: Conditions for western blotting antibodies.
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2.2.5 Membrane Stripping
Membranes requiring re-probing were washed and stripped using a guanidine HCl buﬀer (Yeung
and Stanley, 2009). Briefly, membranes were incubated in stripping buﬀer (6 M guanidine HCl,
0.4% triton X-100, 20 mM tris-HCl pH 7.5, 0.1 M β-mercaptoethanol) for 2 x 5 minutes, with
TBS-T washes 4 x 3 minutes between and after strips. Stripped membranes were then blocked
again for 1 hour in 5% milk/TBS-T prior to antibody re-incubation.
2.2.6 Immunoprecipitation
Cell lysates intended for immunoprecipitation were lysed in a volume of 300-500 µl as described
above. Lysates were pre-cleared by rotation for 10-30 minutes at 4◦C with 10 µl of bead
slurry. Beads were pelleted along with any non-specifically binding proteins for 60 seconds at
13000 rpm at 4◦C, supernatant was transferred to fresh Eppendorf’s. Lysates were incubated
with the desired antibody (see Table 2.4 for details) overnight or for 2-3 hours at 4◦C on a
rotary wheel. Eppendorf’s were next centrifuged at 13,000 rpm for 2 minutes to remove any
precipitated proteins, supernatant was subsequently transferred to a fresh Eppendorf with 30-40
µl of appropriate protein A/G-agarose bead slurry (see Table 2.4 for details). This mix was
rotated at 4◦C for 1-2 hours before centrifugation at 13000 rpm for 1 minute. Beads were washed
4 x in ice cold RIPA buﬀer with inhibitors. Any remaining liquid was completely removed from
Eppendorf’s using a 27G needle and 1 ml syringe. Beads were re-suspended in 20 µl laemmli
with 7 M urea and subject to SDS-PAGE.
2.2.7 Western blot quantification
Image Quant TL software was used for western blotting quantification. Western blot films were
scanned and analysed using the 1D gel analysis software used to normalise the background and
quantify band density signals. All data shown was calculated as a percentage of the control.
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Table 2.4: Conditions of antibodies used for immunoprecipitation.
2.2.8 S35 methionine labelling
Cells were grown to confluence in the required dish size (usually 6 well plates). Methionine
free media was used for the labelling period. Methionine free DMEM supplemented with 10%
FCS and P/S/G at 37◦C was used for BMM, HUVEC, Rat2 fibroblasts and Raw 264.7 cells.
Methionine free RPMI supplemented with 20% FCS and P/S/G at 37◦C was used for MO7E
cell labelling. Cells were labelled in the stated media with 2 MBq/ml S35 methionine for 3
hours, unless otherwise stated. After the label ‘hot’ media was carefully removed and cells were
washed 3 x in PBS and re-incubated in fresh media for the indicated pulse-chase period or for
the 0 hour time point cells were immediately lysed in RIPA, and subject to western blotting or
whole cell extract analysis and immunoprecipitation (see Table 2.4) as stated above. IP lysates
were subject to SDS-PAGE electrophoresis and gels were next dried down onto Whatman paper
using a gel drier apparatus set to 90◦C for 2.5 hours. Autoradiography using Kodak Biomax MR
Film (Sigma) and a film developing machine (Kodak) was used for radioactive signal detection.
2.2.9 Cell surface biotinylation
Cell surface biotinylation was carried out according to Meier et al., (1992). Briefly, BMM cells
were growth to confluence in 10 cm2 dishes. Biotin ester (biotin N-hydroxysuccinimide ester)
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was diluted immediately prior to use in 10 mM Na-borate (pH 8.8) with 150 mM NaCl, to a final
concentration of 50 µg/ml. Cells were washed 1 x in PBS, and biotinylated by incubation with
diluted biotin for 15 minutes at room temperature. The biotinylation reaction was quenched
using 10 mM NH4Cl. Cells were then washed 3 x in an excess of TKM buﬀer (50 Mm Tris-HCl
(pH7.4), 25 mM KCl, 5 mMMgCl2 and 1 mM EGTA). Labelled cells were re-incubated in media
for the intended chase time point, except for the 0 hour time point which was lysed immediately.
Plates were lysed in 1 ml RIPA buﬀer, an aliquot was retained for whole cell extract analysis
and the remaining lysate was immunoprecipitated for FMS. Immunoprecipitates were subject
to SDS-PAGE separation and membranes were probed with a streptavidin-HRP secondary
antibody. Streptavidin-HRP was diluted at 1:1000 in 5% milk/TBS-T and rolled overnight at
4◦C before standard ECL protein detection.
2.3 MTT assay
Cells were plated in 24 well plates to the desired confluence. Treated cells were incubated with
200 µg/ml MTT (thiazolyl blue tetrazolium blue) at 37◦C, 30 minutes prior to experimental
commencement. Media was carefully removed and 200 µl DMSO was added to cells at room
temperature on an orbital shaker for up to 30 minutes. 100 µl of this was then transferred to a
96 well plate and read at 590 nm on a spectrophotometer.
2.4 Immunofluorescence Staining and Analysis
2.4.1 Cell plating fixation, permeabilisation and blocking
Cells were plated at equal densities onto 13 mm2 glass coverslips (VWR) in 24 well plates. Cells
were treated where relevant with vehicle control or drug/ligand. Upon experiment commence-
ment media was removed from wells and 4% paraformaldehyde (PFA) was added to cells at
room temperature for 10-20 minutes. Fixed cells were washes 3 x in PBS and either stored at
4◦C unless cells were to be stained immediately. Permeabilisation was carried out by incubation
with 0.02% Triton X-100/PBS for 2-5 minutes at room temperature. Blocking was carried out
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in 10% FCS/PBS for 20 minutes at room temperature.
2.4.2 Fixed cell staining
Antibodies were diluted in blocking buﬀer at appropriate dilutions (see Table 2.5). 30-40 µl’s
of the diluted antibody was spotted onto the coverslips and incubated for up to 1 hour at
room temperature. Cells were next washed 3 x in PBS and incubated with relevant secondary
antibodies (all at 1:100 dilution) for up to 45 minutes at room temperature in the dark. Cells
were washed 3 x in PBS and 1 x in dH2 0 prior to coverslip mounting using ProLong gold antifade
reagent with DAPI (Invitrogen). Secondary only controls were used throughout all experiments
and single colour staining was used as additional controls for co-staining experiments. All
secondary only controls displayed no background as expected. Slides were stored at room
temperature in the dark. Images were captured on a SP5 confocal microscope and analysed
with LAS AF Lite software.
2.4.3 Live antibody binding
For FMS internalisation and build-up experiments the correct N-terminal FMS antibody was
selected depending on target species (see Table 2.5 for details). Incubations with fluorescently
conjugated antibodies or lysotracker were kept in the dark for the duration of the experiment
and subsequent staining.
For live antibody uptake time course experiments; cells were incubated with the desired antibody
for 20 minutes at 37◦C (see Table 2.5 for details). Cells were then washed 2 x in PBS and re-
incubated with fresh media for the stated chase time point. Cells were then fixed, permeabilised
(where relevant) and incubated with secondary antibodies according to the fixed cell protocol
stated above. For surface loss only analysis cells were not permeabilised.
For antibody internalisation pathway analysis; cells were incubated with the FMS antibody
throughout the 3 hour inhibitor incubation. 30 minutes prior to fixation lysotracker was added
to cells to a final concentration of 1 µM. Cells were then washed 1 x in PBS prior to fixation as
stated previously.
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For antibody internalisation pathway analysis with M-CSF stimulation; cells were incubated
with the relevant FMS antibody (see Table 2.5) and/or inhibitors for 30 minutes prior to M-
CSF and lysotracker addition to relevant wells. Cells were subsequently fixed, permeabilised
and stained for other primary antibodies prior to secondary antibody staining as described for
the fixed cell protocol stated above.
2.4.4 Colocalisation quantification
All lysosomes were counted per cell and 200-300 EEA1 positive compartments were counted
per cell. Lysosomal or EEA1 compartments were isolated and circled, compartments contain-
ing detectable FMS staining in was then counted. Colocalisation was quantified according to
EEA1 and lysosomal compartments found to contain FMS, these were classed as FMS-positive.
Data were displayed as percentage of lysosomal or EEA1 compartments positive for FMS. In
these experiments n=2, ten cells were counted per experiment due to time constraints the final
experiments analysis was not able to be completed and displayed here.
2.5 FACS time course analysis
Cells were grown to confluence in 24 well plates and live antibodies bound as previously described
(see Table 2.5 for antibody conditions). If fluorescently conjugated primary antibodies were used
cells were kept in the dark for the duration of the experiment. Upon time course commencement
cells bound with conjugated primary antibodies were washed 2 x in cold PBS, 300 µl in ice
cold 2% FCS/PBS (0.2 µm filtered) was added, cells were subsequently scraped, transferred
to FACS tubes (BD bioscience) and stored on ice until FACS analysis. Cells incubated with
non-conjugated antibodies (or secondary antibody control cells); cells were washed 2 x in cold
PBS, then incubated in the secondary antibody at a 1:100 dilution in 2% FCS/PBS (0.2 µm
filtered) for 20 minutes at room temperature. Cells were then washed 2 x in cold PBS, 300 µl in
ice cold 2% FCS/PBS (0.2 µm filtered) was added, cells were subsequently scraped, transferred
to FACS tubes (BD bioscience) and stored on ice until FACS analysis.
Controls used were incubated with the secondary only or unstained cells. Cells were briefly
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vortexed before FACS analysis. A total of 10,000 cells per condition were assayed using a BD
FACS Calibur machine. Data presented is displayed as a percentage of fluorescence detected at
time point 0. Background fluorescence was subtracted from each value prior to analysis.
Table 2.5: Conditions for antibodies used for IF and FACS analysis. Immunofluorescence (IF),
fluorescence-associated cell sorting (FACS).
2.6 Senescence staining
Senescence staining was carried out using the β-galactosidase staining kit (Cell Signalling; 9860).
The kit detects β-galactosidase activity at pH 6.0, a characteristic of senescent cells.
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2.7 FMS mutagenesis
FMS mutagenesis was carried out using Invitrogen Strings technology to synthesise the large
DNA fragments required for cloning. Vsn2c-fms is a retroviral construct containing the full 3.1
Kb human c-fms cDNA cloned into the Vsn2 vector (Dibb et al., 1990). The FMS sequence
was mutated by a span of 10 amino acids from the first amino acid of the extracellular domain
and directly swapped with the equivalent region of the PDGFRβ sequence (see Figure 2.1 for
details and cloning sites).
2.7.1 Digestion
Restriction enzyme digests were performed using NEB enzymes in recommended buﬀers for the
indicated times. Reactions were carried out in a final volume of 10 µl. The single FMS cutters
BsrGI and BstXI cloning sites were used to clone in the fragment (see Figure 2.1), these were
verified as single cutters and not able to cut the vsn2 vector.
FMS mutant fragment purchased from Invitrogen was re-suspended in 10 µl TE buﬀer. 5 µl
of the fragment and 2 µg vsn2c-fms was cut with BsrGI and BstXI (both NEB) for 2 hours at
37◦C in buﬀer 3 with 10 µg/ml BSA (see Table 2.6). Reactions were stopped by the addition of
Orange G loading dye (5 x) (0.1% Orange G powder, dissolved in TAE buﬀer (20 x TAE buﬀer:
0.8 M Tris, 0.4 M sodium acetate, 20 mM EDTA, pH 8.0 with acetic acid)) and digestions were
purified using E-gel extraction.
2.7.2 E-gel extraction
Digested DNA intended for isolation was run on thin (3 mm x 75 mm x 75 mm) 1% agarose
TAE gels with 0.5 µg/ml ethidium bromide. Samples were loaded into wells and gels were run
at 50 volts for one to two hours in 1 x E buﬀer using a 1 Kb ladder (NEB). Gels were run in
a horizontal mini-electrophoresis tank. Fragment isolation was carried out by cutting a hole in
the gel immediately below the DNA band visualised using a UV light box. The E-gel was then
replaced in the running tank on a raised platform so only the edges of the gel and wells were
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Figure 2.1: FMS mutagenesis sequence
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Table 2.6: Volumes of ligation reaction set-up. All volumes displayed are in µl’s. T4 DNA
ligase and buﬀer (NEB).
covered in buﬀer. The cut section in the gel was filled with 30-40 µl E-buﬀer and run for 30
seconds at 150 volts. The buﬀer was then extracted and transferred into an Eppendorf. This
step was repeated 3-4 x until the full DNA band had been removed from the gel.
2.7.3 Phenol clean up and ethanol precipitation
Extracted DNA was centrifuged at 13,000 rpm in a bench top centrifuge at room temperature
and supernatant was transferred to a fresh Eppendorf.
DNA precipitation was carried out by adding 1/10th of the volume of sodium acetate pH 5.2,
1 µl glycoblue and 2.5 x the volume of -20◦C ethanol. Samples were left on ice for at least 1
hour and then centrifuged at 13,000 rpm for 10 minutes at 4◦C. Supernatant was removed,
carefully avoiding the pellet and replaced with 70% ethanol before centrifuging at 13,000 rpm
for 5 minutes at 4◦C. The supernatant was then removed and pellet air-dried. DNA from the
vector and fragment was re-suspended in 20 and 30 µl’s TE buﬀer respectively.
2.7.4 Ligation reaction
Ligation reactions were set up in Eppendorf’s with control reactions listed in Table 2.6. Ligation
reactions were allowed to progress at room temperature for 5 hours.
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2.7.5 Transformation of DH5α competent cells with plasmid DNA
Competent DH5α cells were transformed with the full ligation reactions DNA content. 100 µl
of cells were added to the DNA and incubated on ice for 45 minutes prior to heat shock at
42◦C for 45 seconds. Bacteria were incubated on ice for 2 minutes before addition of 500 µl
2 x YT medium. Bacteria were vigorously shaken at 37◦C for 30 minutes prior to 200 µl of
bacteria/media mixture being plated on ampicillin plates.
2.7.6 Plasmid DNA amplification
Following acceptable negative control plates for the ligation reaction above 5-10 colonies were
picked and grown in 5 mls of 2 x YT media with 100 µg/ml ampicillin overnight with vigorous
shaking at 37◦C. Cells were pelleted at 13,000 g for 10 minutes before DNA was purified
using a QIAprep mini-prep plasmid purification kit (Qiagen) according to the manufacturer’s
instructions. DNA concentration was determined by nano-drop after purification.
2.8 Transfections
2.8.1 siRNA knockdowns
All siRNA was obtained from Dharmacon, except for the scrambled siRNA control which was
purchased from Qiagen (1027280). All siRNAs purchased were from the Dharmacon siGenome
set of 4 range (except for the LRP1 which was siGenome mix). Stock siRNA was diluted in
nuclease free distilled water to a final concentration of 20 µM. Final siRNA concentration added
to cells ranged from 10 nM to 100 nM depending on siRNA and cell line being transfected.
Knockdown studies were performed using HiPerfect transfection reagent (Qiagen). Cells were
seeded at 2 x 105 cells per well in a 24 well plate in 100 µl in under normal conditions. 375 µg of
siRNA was next diluted in 100 µl Opti-MEM without FCS giving a final siRNA concentration
of 50 nM. 6 µl of the HiPerfect transfection reagent was added to the siRNA mixture and
vortexed. This was then allowed to incubate at room temperature for 5-10 minutes while
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transfection complexes formed. siRNA was then added dropwise onto cells and incubated for 6
hours. After this the media volume was increased to a total volume of 600 µl and incubated for
24-72 hours before knockdown assaying.
2.8.2 Transient plasmid transfections
Plasmids were transfected into Hek cells using Lipofectamine 2000 (Invitrogen) according to
manufacturer’s instructions. Briefly, Hek cells were grown to 70-90% confluence in 24 well
plates. For a single well; 3 µls lipofectamine was diluted in 50 µl Opti-MEM media in an
Eppendorf, in a separate Eppendorf 1 µg DNA was diluted in 50 µl Opti-MEM media, the two
were then combined, vortexed and incubated for 5 minutes prior to addition to cells. Cells were
assayed 48 hours after transfection.
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Chapter 3
Characterisation of Tools
3.1 Chapter 3: Introduction
The FMS receptor for macrophage-colony stimulating factor (Stanley et al., 1978) is a member
of the class III family of receptor tyrosine kinases and a close relative of the PDGFRβ and c-KIT
receptors (Coussens et al., 1986; Lemmon and Schlessinger, 2010). It is expressed primarily in
cells of the monocyte/macrophage lineage (Byrne, 1981) including, macrophages, osteoclasts,
microglia, dendritic and paneth cells (Bartlemez et al., 1989; Guilbert and Stanley, 1980; Byrne
et al., 1981; MacDonald et al., 2005; Huynh et al., 2009; Nandi et al., 2012) and select cells of
the female reproductive tract (Wei et al., 2010).
FMS is known to be downregulated by two distinct mechanisms. The first being ligand-mediated
endocytosis (Guilbert and Stanley, 1986; Lee et al., 1999) which is dependent upon Cbl-induced
ubiquitination (Lee et al., 1999) and subsequent degradation via the lysosome (Lee et al., 1999,
Wang et al., 1999). M-CSF is known to regulate a wide range of biological processes including
hematopoiesis, inflammatory reactions and aspects of the innate immune response (Chitu and
Stanley, 2006). The second mechanism of FMS downregulation is a two-step proteolysis reaction,
the first cleavage mechanism being mediated by the MMP, ADAM17 (Rovida et al., 2001; Glenn
and van der Geer, 2008), the second cleavage step is mediated by the γ-secretase complex
(Wilhelmsen and van der Geer, 2004; Glenn and van der Geer, 2008). The purpose of FMS
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shedding is currently unknown but has been postulated as essential for the diﬀerentiation of
cells of the monocytic lineage (Hiasa et al., 2009) and also macrophages polarisation (Sester et
al., 1999; Rovida et al., 2001).
3.2 Chapter 3: Results
Treatment with the translation inhibitor cycloheximide (100 µg/ml) revealed that the FMS
receptor was turned over constitutively over a 5 hour time course with a half-life of 1 to 2 hours
(estimated visually from observed data) when expressed exogenously in Rat2 fibroblasts (Figure
3.1A, first panel) or Hek cells (Figure 3.1B). By contrast, the PDGFβ and EGF receptors were
relatively stable under the same conditions (Figure 3.1A, middle and bottom panels). This
result was confirmed by pulse labelling with S35 methionine in Rat2c-FMS cells (Figure 3.1C).
Kinase impairment of the FMS receptor by two mutations, the K616A and G589A substitutions,
previously shown to prevent receptor activation (Uden et al., 1999) display FMS loss at the same
rate as the wild type receptor upon cycloheximide treatment (Figure 3.2, left panel). Deletion
mutants of the FMS receptors juxtamembrane region, kinase insert loop and kinase domain do
not prevent the receptors degradation which can be seen to occur at similar rates (half-life data
approximated by visual estimation) to the wild type receptor and kinase impaired mutants with
cycloheximide treatment (Figure 3.2, right panel).
Two mouse cell lines, Raw 264.7 macrophages and N9 microglia, which endogenously express
the FMS receptor, displayed an accelerated sub-15 minute receptor half-life in response to
cycloheximide treatment (Figure 3.3A and B). S35 methionine pulse labelling of Raw 264.7
cells indicates that the FMS half-life in response to M-CSF stimulation was approximately 30
minutes (Figure 3.3C, third panel), and that the constitutive turnover was approximately 90
minutes (Figure 3.3D, fourth panel) with most mature receptor lost after a 3 hour pulse-chase.
Figure 3.3D also illustrates how the immature FMS band is lost within a 1 hour pulse-chase
as would be expected due to its rapid processing from immature to extensively glycosylated
mature receptor.
The S35 methionine data of Figure 3.3C and D contradicts the turnover data determined by
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the cycloheximide treatment shown in Figure 3.3A and B. To determine how cycloheximide was
inducing an accelerated rate of FMS turnover, Figures 3.4 to 3.7 were performed in the Raw
264.7 and N9 cells. A 3 hour cycloheximide treatment results in an approximate 85% decline
in cell viability 24 hours after drug washout measured by an MTT assay (Figure 3.4A). The
5 hour treatment of Rat2 fibroblasts shown in Figure 3.4B resulted in loose cell adhesion and
mass cytoskeletal rearrangement of F-actin filaments (light blue staining).
Figure 3.1: The FMS receptor is constitutively degraded. A) Rat2c-FMS and B) Hekc-FMS cell
lines were treated with 100 µg/ml cycloheximide for the indicated times. C) Rat-2c-fms cells
were labelled with S35 methionine for 3 hours and then chased with cold methionine for the
indicated times. Ponceau or α-tubulin staining were used as loading controls for the western
blots. Figure 1A carried out by Dr A. Russell.
Cycloheximide treatment of the Raw 264.7 and N9 cells was shown to activate the two eﬀector
caspases, caspase-3 and -7 in a time-dependent manner (Figure 3.5A and B). The standard
apoptosis inducer staurosporine was used as a positive control in these experiments. Western
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Figure 3.2: The constitutive FMS loss is not dependent upon the receptors intrinsic kinase
activity or its intracellular domains. Rat2c fibroblasts expressing wild type FMS or the mutant
receptors, kinase dead 1 and 2 (K616A and G589A substitutions, respectively), or deletion of
the kinase insert loop, juxtamembrane region and kinase domain were treated with 100 µg/ml
cycloheximide (CHX) for the indicated time points. Western blotting analysis for the FMS
receptor was subsequently carried out.
blot data shows the appearance of cleaved caspase-3 in a time-dependent manner, detectable
from 30 minutes cycloheximide treatment (Figure 3.5A and B, middle panels). FMS loss corre-
lated positively with the caspase-3 activation observed (Figure 3.5A and B, top panels). Figure
3.5C shows caspase-3 and -7 activation (green staining) and its nuclear location with both
staurosporine and cycloheximide treatment in comparison to the negative control in Raw 264.7
cells.
As eﬀector caspase activation correlated positively with FMS loss it was next examined whether
FMS is a direct caspase target using two caspase inhibitors in an attempt to stabilise the
receptor after cycloheximide treatment (Figure 3.6). Treatment of Raw 264.7 and N9 cells
in the presence of a caspase-3/7 specific inhibitor (Figure 3.6A) or the pan-caspase inhibitor,
Z-VAD-FMK (Figure 3.6B) failed to abrogate FMS loss.
FMS is known to be subject to ectodomain cleavage so it was next determined whether shedding
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Figure 3.3: FMS loss with cycloheximide treatment and S35 methionine labelling in endogenous
cells. Western blots showing the FMS half-life in A) Raw 264.7 and B) N9 cells after 100
µg/ml cycloheximide treatment. C, D) Raw 264.7 cells were S35 methionine pulse-labelled and
lysates were immunoprecipitated for FMS with or without M-CSF stimulation for the indicated
minutes.
was responsible for the accelerated FMS loss observed after cycloheximide insult. The broad
spectrum MMP inhibitor, TAPI-0 was able to partially abrogate the FMS loss at a concentration
that eﬀectively blocks shedding with TPA stimulation, (Figure 3.7A and B, left panels) giving
FMS a half-life extension from sub-15 minutes to 30-60 minutes (Figure 3.7A and B, right
panels).
Treatment of Raw 264.7 and N9 cells with 100 µg/ml cycloheximide was shown to induce
apoptosis and FMS loss, possibly by shedding activation (Figures 3.3 to 3.7). It was next
examined in Figure 3.8 whether a lower inhibitor concentration would still block translation
without the adverse eﬀects. A titration of the drug in Raw 264.7 cells demonstrated that
concentrations less than and equal to 0.1 ng/ml did not decrease cell viability but concentrations
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Figure 3.4: Cell viability is reduced after cycloheximide treatment. Treatment for 3 hours
with 100 µg/ml cycloheximide results in A) reduced viability in MTT assays carried out after
drug washout and 24 hour recovery period in Raw 264.7 cells and B) F-actin disruption after
treatment Rat2c-FMS cells were fixed, permeabilised and stained with phalloidin (light blue).
Cell nuclei were stained using DAPI (dark blue). Scale bar represents 25 µm
equal to and above 10 ng/ml induced a concentration dependent decrease in viability over the 5
hour treatment, determined by an MTT assay (Figure 3.8A). Raw 264.7 cells were subsequently
treated with a titration of cycloheximide and lysates analysed by western blotting in Figure
3.8B to determine eﬀectivity at translation inhibition (loss of the FMS immature band) and
absence of shedding induction (presence of mature band). Translation was inhibited fully at
concentrations over 1 µg/ml, and partially with 10 ng/ml cycloheximide. Shedding was induced
by concentrations greater than and equal to 1 µg/ml cycloheximide.
Work on the constitutive pathway in the endogenous Raw 264.7 and BMM cells requires further
tools to rule out autocrine stimulation. Two FMS kinase inhibitors GW2580 (Conway et al.,
2005) and Imatinib (Taylor et al., 2006) were characterised in Figures 3.9 to 3.12. Figure
3.9 shows the inhibition of phosphorylation of FMS after M-CSF stimulation by GW2580 upon
Rat2c-FMS (Figure 3.9Ai), the Rat2-T663I FMS mutant (Figure 3.9Aii) and the Raw 264.7 cells
(Figure 3.9Aiii). GW2580 displayed a concentration dependent phospho-inhibition of tyrosine
723 (located on the kinase insert region), with an IC50 value of 10-50 nM in wild-type FMS in
both the Rat2c-FMS and Raw 264.7 cell lines (Figure 3.9Ai and iii, respectively) but displayed
no inhibitory eﬀect upon the Rat2-T663I FMS mutant (Figure 3.9Aii). GW2580 was shown
to be equally eﬀective at c-FMS phospho-inhibition in culture from 1 hour up to 48 hours
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Figure 3.5: Cycloheximide treatment activates the eﬀector caspases. Treatment with 100 µg/ml
CHX or 1 µM staurosporine activates caspase-3 in A) Raw 264.7 and B) N9 cells. C) Caspase-3
and -7 (green staining) activation by cycloheximide (100 µg/ml) in Raw 264.7 cells. Immunoflu-
orescence superimposed on a bright field background. Nuclei stained with DAPI (blue). Scale
bar represents 25 µm.
incubation, but retained no activity after 72 hours (Figure 3.9B).
As expected, BMM cell viability, which is dependent upon M-CSF, was reduced after treatment
with GW2580 (Figure 3.10A) or Imatinib (Figure 3.10B) in an inhibitor-concentration and time
dependent manner over 24 (blue bars) and 48 (red bars) hours, as shown by an MTT assay.
Imatinib treated cells displayed the most prominent reduction in cell viability at the highest
concentration tested in comparison to the M-CSF starved or GW2580 treated cells.
FMS is downregulated in response to M-CSF stimulation. It was next determined whether
GW2580 and Imatinib are able to inhibit the M-CSF induced degradation. Stimulation with
M-CSF for a time course of up to 3 hours resulted in a decrease in mature FMS levels in the
Rat2c-FMS (Figure 3.11A), Rat2-T663I (Figure 3.11B) and Raw 264.7 cells (Figure 3.11C).
This degradation was fully prevented in response to GW2580 treatment and partially prevented
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Figure 3.6: Caspase inhibition does not delay cycloheximide-induced FMS loss. Raw 264.7 or
N9 cells were pre-treated with 50 µM of A) a caspase-3/7 inhibitor or B) a pan-caspase inhibitor
Z-VAD-FMK before treatment with 100 µg/ml cycloheximide or 1 µM staurosporine for the
indicated times.
in response to Imatinib treatment in the Rat2c-FMS (Figure 3.11A) and Raw 264.7 cells (Figure
3.11C) but not the Rat2-T663I cells (Figure 3.11B).
The eﬀect of both kinase inhibitors upon cellular distribution of the unstimulated FMS receptor
was characterised by immunofluorescence staining of total FMS in the Rat2c-FMS and Rat2-
T663I mutant and surface FMS in Raw 264.7 cells (Figure 3.12). GW2580 was found to have no
eﬀect upon the cellular distribution of FMS in any of the cell lines tested (Figure 3.12, middle
column) while Imatinib (Figure 3.12, right column) was found to cause distinctive clustering of
the wild type receptors in the Rat2c-FMS and Raw 264.7 cells (top and bottom panels), but had
no eﬀect on FMS distribution in the mutant Rat2-T663I (middle panel) in comparison to the
vehicle treated control cells (Figure 3.12, left column). The Imatinib-induced FMS clustering is
likely to alter the receptor distribution on the cell surface as the Raw 264.7 cells were stained
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Figure 3.7: Broad spectrum MMP inhibition partially stabilises FMS after cycloheximide insult.
A, C) 10 µM TAPI-0 inhibits shedding by 10 µM TPA stimulation in Raw 246.7 and N9 cells.
B,D) Time course of 100 µg/ml cycloheximide treatment in the presence of 10 µM TAPI-0 for
Raw 246.7 and N9 cells. Figure 3.7 carried out by Dr A. Russell.
solely for surface receptor (Figure 3.12, bottom panel).
We next characterised FMS shedding in Raw and bone marrow macrophages (Figures 3.13-
3.24) as a first step towards establishing whether constitutive FMS degradation occurs by a
distinctive pathway. Mature FMS is lost in a concentration (Figure 3.13A) and time-dependent
(Figure 3.13B) manner in response to TPA treatment in Raw 264.7 cells. This loss correlated
positively with ERK activation (Figure 3.13A, middle panel). The FMS ICD can be observed in
Figure 3.13B as the 55 kDa band present after shedding induction. Immunofluorescence images
also show that the mature, cell surface FMS staining (red) is rapidly lost in response to TPA
stimulation in Raw 264.7 cells (Figure 3.13C). The remaining FMS staining observed in Figure
3.13C colocalises to the Golgi (green staining) and is not lost throughout the TPA time course.
100 nM was determined as the optimal TPA concentration for use in further experiments and
is commonly used in the literature.
Treatment of Raw 264.7 cells with TPA causes a cellular distribution change of both ADAM17
and total phospho-tyrosine residues in cells demonstrated by immunofluorescence in Figures
71
Figure 3.8: Raw 264.7 cells treated with a titration of cycloheximide from 100 µg/ml to 1 pg/ml
display concentration dependent eﬀects on cell viability, shedding induction and translation
inhibition over 5 hours. A) MTT assay of cell viability after cycloheximide titration. Results
are representative of 3 experiments, error bars represent SEM. B) Western blot representative of
two independent experiments showing the eﬀect on FMS levels that a titration of cycloheximide
has in the absence (-) or presence (+) of 20 µM TAPI-0.
3.14A and 3.14B, respectively. The distribution of both ADAM17 and total phospho-tyrosine
staining (red and green respectively) can be observed as changing from a peri-nuclear location
in untreated cells to membrane and cytosolic after 15 minutes TPA treatment. There was no
noticeable change in nuclear staining upon treatment for either staining group.
The relationship of FMS kinase inhibition and the ability of the receptor to undergo shedding
was next determined in order to rule out any possible cross-talk between the two pathways
(Figure 3.15). Shedding was induced with TPA after pre-incubation with a titration of GW2580
(Figure 3.15A) and Imatinib (Figure 3.15B) in Raw 264.7 cells. Mature FMS was lost to the
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Figure 3.9: GW2580 inhibits wild type FMS autophosphorylation in a concentration-dependent
manner for up to 48 hours in cell culture. A) Western blot showing the eﬀect of 1 hour pre-
treatment of GW2580 at the indicated concentrations on FMS phosphorylation after M-CSF
stimulation on i) Rat2c-FMS, ii) Rat2-T663I and iii) Raw 264.7 cells. B) Rat2c-FMS cells were
treated with 150 nM GW2580 for the indicated number of hours and subsequently stimulated
with M-CSF. Ligand stimulation was carried out with 5 x 103 U/ml M-CSF for 5 minutes.
Experiments performed by Marian Zitti.
same extent as the TPA only treated cells in the presence of both kinase inhibitors at all
concentrations tested.
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Figure 3.11: GW2580 abrogates M-CSF induced downregulation of wild type FMS. Western
blot data comparing the abilities of GW2580 and Imatinib to abrogate M-CSF induced FMS
downregulation in A) Rat2c-FMS, B) Rat2-T663I and C) Raw 264.7. Cells were pre-incubated
with either 150 nM GW2580 or 10 µM Imatinib for 30 minutes prior to stimulation with 5 x
103 U/ml M-CSF for the indicated time point. Experiments performed by M. Zitti.
Corresponding to the loss of mature FMS in cell lysates upon TPA-induced shedding induction
the FMS ECD can be detected in the media as a fragment of approximately 100 kDa’s with the
use of an antibody against the extracellular domain of the receptor (Figure 3.16). This band
is largely undetectable in the absence of TPA stimulation or with use of the broad-spectrum
shedding inhibitor, TAPI-0, indicating its specificity.
Treatment with TAPI-0 for 16 hours does not result in a build-up in the levels of mature FMS
receptor (Figure 3.17, compare lane 1 and 2). TPA treatment induces mature FMS loss almost
75
Figure 3.12: The eﬀect of kinase inhibitors on FMS cellular distribution. Rat2c-FMS (top
panel), Rat2-T663I (middle panel) and Raw 264.7 (bottom panel) were treated with vehicle
only, 150 nM GW2580 or 10 µM Imatinib for 1 hour prior to cell fixation and staining. Rat2c-
FMS and Rat2-T663I were stained for total FMS and Raw 264.7 cells for surface FMS. Scale
bars represent 7.5 µm, 10 µm and 5 µm on top, middle and bottom panels respectively.
completely within a 15 minute treatment and the ADAM10 activator, ionomycin (IO) treatment
resulted in a slight decrease in mature FMS levels.
The FMS ICD released by the γ-secretase complex after shedding induction is reported to
be highly unstable which was confirmed here in Figure 3.18A and B (absence of detectable
ICD band in lane 2) in Raw 264.7 cells. A titration with a gamma-secretase inhibitor (GSI),
to prevent the regulated intra-membrane proteolysis (RIP) cleavage step which releases the
intracellular domain (ICD) of FMS alone, does not result in a build-up of the FMS ICD (Figure
3.18A, lanes 3-7). TPA treatment alone likewise does not yield a detectable FMS ICD band
(Figure 3.18A lanes 2 and 8, and Figure 3.18B, lane 2). A titration of GSI in the presence of
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Figure 3.13: FMS is rapidly lost upon TPA treatment in Raw 264.7 cells. Western blot analysis
of: A) the eﬀect of a 30 minute TPA titration on FMS levels and ERK activation and B) time
course of TPA treatment. C) immunofluorescence analysis of a time course of TPA treatment
displaying FMS (red) and the Golgi marker giantin (green). Nuclei stained with DAPI (blue).
Scale bars depict 7.5 µM.
TPA demonstrated stabilisation of the FMS ICD in a concentration dependent manner with
maximal stabilisation with 5 µM GSI (Figure 3.18A, lanes 9-12). ERK is demonstrated to
be activated upon TPA treatment and unaﬀected by the GSI treatment at any of the tested
concentrations. GSI and the proteasomal inhibitor, MG132 were shown to stabilise the ICD
to similar extents after TPA stimulation (Figure 3.18B). Immunofluorescence shown in Figure
3.18C confirms the ICD stabilisation observed by western blotting in Figure 3.18B.
TPA-induced FMS shedding was partially abrogated by 100 nM of the inhibitor Go6983 against
PKC isoforms α, β, γ, δ and ζ but not at lower concentrations (Figure 3.19A and B). Treatment
with Go6983 at the tested concentrations had no discernable eﬀect on ERK activation status.
TPA-induced FMS shedding was shown to require ERK activation in Figure 3.19C and D. A
titration of the ERK inhibitor U0126 demonstrated a concentration dependent abrogation of
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Figure 3.14: ADAM17 and total phospo-tyrosine protein staining upon TPA treatment in Raw
264.7 cells. Cells were treated with 100 nM TPA for 15 minutes and stained for A) total
ADAM17 (red) or B) total phospho-tyrosine (green). Nuclei stained with DAPI (blue). Scale
bars depict 50 and 7.5 µM respectively for wide and zoomed views.
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Figure 3.15: Kinase inhibitors do not aﬀect the ability of FMS to be shed upon TPA stimulation
in Raw 264.7 cells. Cells were pre-incubated for 1 hour with the indicated concentrations of
A) GW2580 or B) Imatinib prior to shedding induction with 100 nM TPA for 15 minutes.
Experiments performed by Marian Zitti.
Figure 3.16: After TPA treatment the FMS extracellular domain can be detected in the media
at approximately 100 kDa with an antibody against an extracellular epitope in Raw 264.7 cells.
Cells treated with vehicle control, 100 nM TPA for 15 minutes or with 20 µM TAPI-0 only.
mature FMS loss corresponding to loss of ERK activation with TPA treatment. Concentrations
of 5-20 µM U0126 all inhibited ERK activation to the same extent and abrogated any detectable
FMS shedding induction.
The inactive rhomboid protein, iRhom2 is implicated as being required for shedding of select
ADAM17 substrates. FMS shedding was shown to be partially abrogated by two of the siRNAs
targeting iRhom2 in comparison to the scrambled siRNA control in Hekc-FMS cells (Figure
79
Figure 3.17: The FMS receptor is not constitutively shed in Raw 264.7 cells. Cells were treated
with 20 µM TAPI-0 for 16 hours, 100 nM TPA for 15 minutes, or 5 µM ionomycin (IO) for 30
minutes. Lysates were subject to western blotting to determing mature FMS loss or gain.
3.20). Mature ADAM17 (bottom band of the doublet) levels were not decreased by the siRNA
(Figure 3.20, bottom panel).
FMS shedding was determined to be induced by a variety of conditions and treatments in Raw
264.7 macrophages including cycloheximide (Figure 3.7) stimulation with the ADAM10 acti-
vator, ionomycin, conditions of lactic acidosis, hypoxia, methyl-β-cyclodextrin, LPS induced
polarisation and the vacuolar type H+ATPase inhibitor bafilomycin A1 (Figures 3.21A to F,
respectively). It was also shown in Figure 3.22 that change of media in the Raw 264.7 cells in-
duces FMS shedding by an ERK independent mechanism. Loss of staining confirmed this in the
immunofluorescence data shown in Figure 3.22B. None of these conditions have previously been
strongly implicated as inducing FMS shedding and suggest FMS is a very sensitive substrate of
ADAM17 with a possibly unknown function.
Considering the readiness of the FMS receptor to be shed under a variety of conditions and
treatments it was next examined whether or not the released FMS ICD has any signalling
capabilities using the kinase inhibitor GW2580 (Figure 3.23). FMS shedding was induced by
stimulation with TPA, IO and two diﬀerent cycloheximide time points, in the presence or
absence of GW2580. No major diﬀerences were observed in the phosphorylation statuses of
ERK, P38, MAPKAPK2, SAPK and c-Jun in the presence or absence of the FMS kinase
inhibitor.
To determine the FMS ADAM17 cleavage site we carried out the initial work shown in Figure
3.24. Treatment with TPA over a 40 minute time course in the Rat2c-FMS cell line showed
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Figure 3.19: TPA-induced FMS shedding is dependent upon ERK activation in Raw 264.7
cells. The eﬀect of A) PKC inhibition with Go6983 and C) ERK inhibition with U0126 on
TPA-induced FMS shedding and quantification of B) Go6983 and D) U0126 data. Treatment
with 100 nM TPA for 15 minutes was carried out. Quantification shown is representative of
3 independent experiments using an unpaired T-test and includes SEM error bars. ns = not-
significant. Replicate experiments performed by Marian Zitti.
that the closely related PDGFRβ is not cleavable under the same conditions FMS is shed
under (Figure 3.24A). These diﬀerences may be due to the receptors diﬀering extracellular
juxtamembrane domains, Figure 3.24B. This was tested by creating a mutant FMS receptor
with a 10 amino acid swap directly after the transmembrane domain of FMS with the same
section of the PDGFRβ (Figure 3.24C). The mutant receptor was shown to be phosphorylated
in response to M-CSF to the same level as the wild type receptor, (Figure 3.24D). Upon TPA
stimulation the mutant receptor is however not obviously shed in comparison to the wild type
Hekc-FMS (Figure 3.24D).
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Figure 3.20: Knockdown of iRhom2 in Hekc-FMS cells partially abrogates FMS loss in response
to TPA stimulation. 4 diﬀerent siRNAs targeting iRhom2 (1-4) or a combination of all 4
(mix) in comparison to the scrambled siRNA control (Sc) were incubated for 48 hours at a
final concentration of 50 nM. Cells were then treated with 100 nM TPA for 15 minutes prior
to lysis and mature FMS levels analysis by western blotting. A) Representative western blot
showing FMS and ADAM17 levels. B) Quantification of FMS TPA-induced shedding after
siRNA treatment. Asterisk denotes data that are statistically significant, with one asterisk
denoting significance with a p value above 0.05, and dual asterisk representing data displaying
a p value above 0.01. Data shown is representative of three independent experiments with SEM
error bars.
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Figure 3.23: FMS ICD does not exhibit any detectable kinase activity. FMS shedding was
induced by 15 minutes treatment with 100 nM TPA or 1 hour 5 µM ionomycin, 15 and 30
minutes 100 µg/ml cycloheximide in the presence or absence of 150 nM GW2580.
86
Figure 3.24: A 10 amino acid PDGFRβ substitution within the FMS extracellular juxtamem-
brane domain confers resistance to shedding. A) Comparison of the eﬀect of TPA upon FMS
and PDGFRβ levels in the Rat2c-FMS cell line. B) Comparison of the transmembrane and
section of the extracellular human FMS and PDGFRβ amino acid sequences. C) 10 amino acid
substitution of PDGFRβ into FMS sequence. D) Western blot of Hek cells transfected with
either c-FMS or the 10 amino acid FMS mutant treated with 100 nM TPA for 15 minutes or 5
x 103 U/ml M-CSF 5 minutes.
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3.3 Chapter 3: Discussion
When FMS was expressed exogenously in Rat-2 fibroblasts or HEK cells it had a half-life of
1-2 hours in the absence of M-CSF, as assayed by cycloheximide treatment or S35 methionine
labelling (Figure 3.1). This constitutive loss was in contrast to the PDGFβ and EGF receptors,
which were relatively stable under the same conditions (Figure 3.1A). A series of FMS mutants
including two kinase impaired receptors with key residues mutated to alanines and three intra-
cellular domain mutant receptors were all shown to turn over in the same manner as the wild
type receptor (Figure 3.3) indicating that the observed degradation it is unlikely to be due to
a mechanism regulated by these domains.
We next asked if FMS was constitutively turned over in macrophage cell types that normally
express FMS. Both cycloheximide treatment and S35 methionine labelling showed that FMS
was unstable in the absence of M-CSF in Raw 264.7 cells and primary macrophages, however,
only the S35 methionine labelling results (Figure 3.3D) were comparable to the Rat-2cFMS
results (Figure 3.1); surprisingly cycloheximide treatment indicated that the FMS receptor was
degraded more rapidly in the absence of M-CSF than in its presence (Figure 3.3A and C).
Cycloheximide is known to have a number of eﬀects upon cells in addition to the inhibition of
translation (Martin et al., 1990; Croons et al., 2007). We showed that cycloheximide reduced
cell viability and induced apoptosis and caspase activation at all concentrations tested that were
also able to inhibite FMS translation (Figures 3.4 to 3.8). Inhibition of caspase activity did not
prevent the loss of FMS following cycloheximide treatment, indicating that caspases were not
directly inducing FMS loss (Figure 3.6).
It is known that shortly after apoptosis induction the sheddase ADAM17 is activated and
this enzyme is able to cleave FMS and many other cell surface receptors and ligands (Rovida
et al., 2001, Glenn and van Der Geer, 2007, Wilhelmsen and Van Der Geer, 2004; Murphy,
2008). Figure 3.7B and D demonstrated the ability of the broad spectrum MMP inhibitor,
TAPI-0 to delay FMS loss upon cycloheximide insult resulting in a half-life extension from
approximately 15 minutes to having detectable levels after 90 minutes treatment. This implies
that the mechanism of cycloheximide-induced FMS loss is via shedding activation. In further
support of this, the apoptosis inducer staurosporine in Raw 264.7 cells resulted in a loss in the
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mature form of the receptor while the immature receptor was unaﬀected (Figures 3.5 and 3.6A
and B), a characteristic of shedding induction. The incomplete restoration of FMS levels with
TAPI-0 treatment in Figure 3.7 is likely to be due to the reported ‘all or nothing’ shedding
induction previously reported (Rovida et al., 2001). We also demonstrate that FMS appears to
be an extremely sensitive substrate of ADAM17 (Figures 3.21 and 3.22) in comparison to other
receptors tested (data not shown).
Cycloheximide was subsequently abandoned as a tool for examining FMS constitutive degra-
dation in macrophage cells. Macrophage cells were also found to be particularly sensitive to
cycloheximide-induced apoptosis by Croons et al., (2007). The authors used the drug to selec-
tively clear macrophages from atherosclerotic plaques in rabbit carotid arteries.
The Rat2 fibroblast cells have been extensively used as model system for studying FMS receptor
activation and degradation in these cells it has been established that FMS has no detectable
kinase activity in the absence of exogenously added M-CSF (Skobridis et al., 2010; Brownlow
et al., 2009; Brownlow et al., 2008). The kinase inactive mutants are also still constitutively
degraded along with a series of intracellular domain mutants tested (Figure 3.2) (Taylor et al.,
2006; Uden et al., 1999; Morley et al., 1999). However it was important to rule out any role
of autocrine ligand stimulation in the constitutive degradation in endogenous FMS expressing
macrophages. Here we found that there was very little detectable phosphorylation of the FMS
receptor expressed in the Raw 264.7 cells in the absence of M-CSF (Figure 3.9Aiii). We also
wanted to identify a good kinase inhibitor of FMS as a further means of controlling for any
possible autocrine stimulation of FMS. Figures 3.9-3.12 and 3.15 were performed comparing
two previously reported FMS kinase inhibitors, Imatinib (Taylor et al., 2006) and GW2580
(Conway et al., 2005).
Imatinib has previously been demonstrated to fully inhibit FMS phosphorylation at a concen-
tration of 10 µM with an IC50 value of 0.3 µM (Taylor et al., 2006). As expected (Conway
et al., 2006), GW2580 was demonstrated to consistently inhibit FMS phosphorylation in the
wild-type receptor after a 5 minute M-CSF treatment in a concentration dependent manner
with an IC50 value between 10-50 nM (Figure 3.9Ai and iii). The inhibitor was unable to pre-
vent the activation of the Rat2-T663I FMS mutant at any of the tested concentrations (Figure
3.9Aii). This mutation is characterised by an amino acid substitution of threonine to a bulky
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isoleucine at the entrance of the ATP pocket (Azam et al., 2008) at residue 663 in FMS and
so blocks access of many small molecule inhibitors such as Imatinib and GW2580 to the ATP
pocket, while leaving ATP’s passage into the kinase domain unhindered and free to carry out
the γ-phosphoryl transfer activating the kinase. We also determined that GW2580 is stable in
culture and able to fully inhibit FMS autophosphorylation for at least 48 hours (Figure 3.9B).
Ligand-induced downregulation of receptors is a well-established mechanism of signalling atten-
uation (Opresko et al., 1995; Seaman et al., 1996). FMS is no exception to this, upon M-CSF
binding the receptor:ligand complex is internalised and degraded within 60 minutes of ligand
stimulation (Figure 3.3C; Downing et al., 1989; Carlberg et al., 1991). GW2580 at the previ-
ously determined concentration of 150 nM was able to fully impede the reduction in mature
c-FMS levels induced by M-CSF stimulation (Figure 3.11A) and as expected GW2580 could
not prevent the downregulation of the T663I mutant (Figure 3.11B). Imatinib at 10 µM gave
similar results to GW2580, although it was slightly less eﬀective (Figure 3.11, right western blot
panel).
Surprisingly, Imatinib treatment resulted in a marked change in distribution of FMS in the
Rat2c-FMS and Raw 264.7 cells. The cause of this distribution change can be attributed to
the direct binding of Imatinib to the receptor, as the distribution of the T663I FMS mutant
remained unaﬀected. Due to the slight non-specific eﬀects of Imatinib in the BMM cell viability
test (Figure 3.10B), the incomplete inhibition of M-CSF induced degradation in the Raw 264.7
cells (Figure 3.11C) and the alteration of FMS distribution (Figure 3.12) GW2580 was selected
as the optimal kinase inhibitor to use in further studies of the constitutive pathway (see Chapter
4).
We next characterised FMS shedding in Raw 264.7 cells and bone marrow macrophages (Figures
3.13-3.24) as a first step towards establishing whether constitutive FMS degradation occurs by a
distinctive pathway (see subsequent Chapters). FMS shedding results in the release of a readily
detectable 100 kDa fragment into the cell media (Figure 3.16). The receptor was demonstrated
in Figure 3.17 to not undergo constitutive basal shedding, shown by the lack of a build up in
mature FMS levels. The ability of the receptor to be shed after induction by TPA and ionomycin
was confirmed (Figure 3.17). The remaining membrane tethered 55 kDa ICD was confirmed
by inhibitor studies to be cleaved a second time by the γ-secretase complex and subsequently
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rapidly degraded via the proteasome (Figure 3.18). The lack of an ICD band in the GSI treated
cells in Figure 3.18 confirmed that FMS is unlikely to be shed at a basal rate in unstimulated
cells as was indicated by Figure 3.17. FMS shedding was demonstrated to be unaﬀected by
the addition of kinase inhibitors, confirming that shedding and M-CSF induced degradation are
distinctive mechanisms (Figure 3.15).
TPA-induced FMS shedding was indicated as being dependent upon ERK activation (Figure
3.19C and D). The involvement of PKC in this process was unclear; the inhibitor Go6983 is
able to inhibit several diﬀerent PKC isozymes at diﬀerent IC50 values (IC50 = 7 nM for PKCα
and PKCβ; 6 nM for PKCγ; 10 nM for PKCδ; and 60 nM for PKCζ) however it does not
inhibit all isoforms. Our data indicate that at 60 nM there may have been partial shedding
inhibition (Figure 3.19A and B), however this cannot be attributed to a single isoform and is
not as convincing as the ERK inhibition data.
TPA stimulation caused a notable but unsurprising alteration in the cellular distribution of
ADAM17 from perinuclear to membrane staining after a short TPA stimulation (Figure 3.14A;
Soond et al., 2005). The addition of TPA also increased the amount of total phosphotyrosine
staining outside of the perinuclear region (Figure 3.14B). We observed a reduction in FMS
shedding induced by TPA stimulation for all of the siRNAs tested against iRhom2 (Figure
3.20B), which indicates a role for iRhom2 in FMS shedding. There is no commercially available
specific antibody against iRhom2 therefore limiting the reliability of our data.
A wide range of stimuli were shown to be able to induce FMS shedding in addition to TPA
(Figures 3.7, 3.13, 3.21 and 3.22), which suggests that there may be a link between FMS shedding
and cellular stress. The ADAM10 activator, ionomycin induced FMS shedding, however this
was only detectable after 30 minutes to 1 hour stimulation (Figure 3.17). Ionomycin is also
known to be an activator of ADAM17 to a lesser extent over a longer time period (Le Gall et
al., 2009), supporting that ADAM17 is likely to be the primary sheddase cleaving FMS (Rovida
et al., 2001; Glenn and van der Geer, 2008).
The conditions common to solid tumours were experimentally mimicked in order to determine
their eﬀect upon FMS levels and shedding. Hypoxia and lactic acidosis were both shown to
induce FMS shedding (Figures 3.21A and B) in a time dependent manner. The lactic acid
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treatment also induced a morphological change in BMM cells over 24 hours which appeared
distinct from the morphological changes induced by polarisation with IL-4 or LPS, potentially
indicating that a state of lactic acidosis may induce a distinct macrophage polarisation state
(data not shown).
I tested whether the FMS ICD may be involved in signalling initiation after shedding induction
by using the highly specific FMS inhibitor, GW2580 (Figure 3.23). None of the signalling
intermediaries that were activated by TPA, IO or cycloheximide were aﬀected by GW2580
indicating that the FMS ICD has no signalling potential, which is consistent with its extremely
rapid degradation (Figure 3.18A).
Polarisation of macrophages by LPS to the M1 phenotype and IL-4 to the M2 phenotype both
induce FMS shedding for up to 24 hours (Sbarba et al., 1996; Guilbert and Stanley, 1984).
We hypothesise that FMS shedding may be required during the cell polarisation process as a
mechanism to enable the signalling of other RTKs to become more prominent in the absence
of potent FMS signalling. This would be interesting in future to test in the BMM cells by
transfection of the non-cleavable FMS mutant receptor shown in Figure 3.24 and characterisation
of the cells ability to undergo polarisation.
Mutagenesis studies were performed to identify the region of FMS cleavage by shedding which
at the time of this research was unknown and to make a mutant FMS that could not be shed.
These were carried out by use of a series of chimeric receptors swapping smaller sections of
the amino acids directly in the juxtamembrane extracellular domain with the corresponding
residues of the closely related but non-sheddable PDGFRβ (Figure 3.24). The cleavage site
was narrowed down to a region of 10 amino acids in the extracellular juxtamembrane domain
(Figure 3.24D). This research has since been confirmed by Vahidi et al., (2014) which determined
the cleavage site to be between the 8th and 9th residues post transmembrane domain. The γ-
secretase cleavage site was also determined in this paper as between the 4th and 5th leucine
residues into the transmembrane domain.
The function of FMS shedding is unknown, however it has been suggested by multiple groups
that there may be a link between its cleavage and cell polarisation or even enable monocytic
diﬀerentiation into the lineages vast range of cell types. Sester et al., (1999) suggested that FMS
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signalling withdrawal after shedding induction occurring upon macrophage activation may aid
the cells immunomodulatory functions. This theory was also suggested by Rovida et al., (2001).
FMS shedding has also been implicated as being essential to the diﬀerentiation of monocytes into
dendritic cells (Hiasa et al., 2009). The physiological role of FMS shedding therefore remains
unknown. Recent work (Vahidi et al., 2014) on non-cleavable FMS mutants should hopefully
shed some light on this aspect of FMS biology.
Importantly our characterisation of shedding and of ligand-induced degradation has identi-
fied both inhibitors and assays that were subsequently used to determine whether constitutive
degradation of FMS operates by a distinctive pathway.
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Chapter 4
The Constitutive Degradation of the FMS
Receptor
4.1 Chapter 4: Introduction
Regulation of the levels of RTKs available at the cell surface is a vital aspect of cellular home-
ostasis. If levels of available RTKs on the plasma membrane are too high this renders the cell
hyper-responsive to growth factors, conversely if the levels are too low cells are unable to re-
spond suitably to their environment (Miaczynska, 2014). Receptor level dysregulation is highly
detrimental to normal cellular homeostasis and can lead to human diseases such as cancer,
diabetes and atherosclerosis to bone disorders (Lemmon and Schlessinger, 2010; Mellman and
Yarden, 2013; Schlessinger, 2014).
Bone marrow derived macrophages (Guilbert and Stanley, 1980) and osteoclasts (Byrne et al.,
1981) are derivatives from monocyte precursors and express the FMS receptor at high levels
(Guilbert and Stanley, 1980; Byrne et al., 1981; MacDonald et al., 2005). FMS is essential
in these cell types and given its oncogenic potential (Sherr et al., 1985) is subject to tight
regulation. Having characterised a range of tools for FMS kinase and shedding inhibition in the
previous chapter we next used these tools to determine the FMS protein turnover in endogenous
cells. We additionally determined the c-KIT and VEGFR2 receptors turnover in the MO7E
94
and HUVEC cell types, two other RTKs essential for their expressing cell types and therefore
predicted to be subject to tight protein level regulation.
4.2 Chapter 4: Results
In order to establish whether FMS shedding is involved in turning over FMS in macrophages, the
experiments shown in Figures 4.1 to 4.4 were performed. Figure 4.1A shows that the rapid and
complete loss of FMS induced by TPA addition to Raw 264.7 or BMM cells can be prevented
by the addition of either of the two broad spectrum MMP inhibitors, TAPI-0 or batimastat.
In contrast Figure 4.1B illustrates that the slower constitutive loss of FMS from Raw cells and
BMM that occurs over a 5 hour period is not inhibited by either TAP1-0 or batimastat. It
should be noted that in Figure 4.1A, TAPI-0 and batimastat were added to cells 5 hours prior
to the addition of TPA, indicating the inhibitors eﬀectivity over the 5 hour time period used in
Figure 4.1B.
To further confirm that shedding is not responsible for the constitutive turnover of FMS we
assayed the end-products of shedding by using an inhibitor against the γ-secretase complex
called GSI, which inhibits a step in shedding illustrated in Figure 4.2A. As expected a 16 hour
incubation of Raw 264.7 cells with GSI or TAPI did not increase FMS levels (Fig 4.2B). In
contrast to TAPI-0, GSI did not prevent loss of mature FMS in response to TPA but instead
resulted in a build-up of the FMS intracellular domain (ICD) over a 5 hour time course (Fig
4.2C). The combination of GSI and TAPI-0 yielded no mature FMS loss and no observable
increase above background levels of the ICD band. Fig 4.2D quantifies the ICD build-up in
cells that were pre-incubated with GSI for 5 hours and then treated with TPA for 15 minutes,
it can be seen that the ICD level increases by at least ten-fold compared to the control data.
This experiment also shows that GSI is still active 5 hours after its addition to cells.
In the presence of TAPI-0 and GSI mature FMS was lost over the 5 hour S35 pulse-chase
experiment shown in Figure 4.3A at the same rate as previously determined in both the Raw
264.7 and BMM, confirming the results of Figure 4.1. Furthermore, TPA stimulation in the
presence of GSI can be seen to stabilise a large amount of a 55 kDa ICD protein band (lane
4, Figure 4.3A). By contrast, the loss of FMS in lanes 8 and 12 is not accompanied by a
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corresponding increase of a 55 kDa protein.
Treatment of Raw 264.7 and BMM cells with both TAPI-0 and GW2580 in Figure 4.4 did not
prevent or even inhibit constitutive FMS loss, strongly indicating that this process does not
occur by shedding or by autocrine downregulation by M-CSF.
All of the previous BMM results were obtained with senescent cells. Figure 4.5A shows BMM
cellular senescence can be determined by the increasing amounts of β-galactosidase staining
(blue staining) over time in culture after diﬀerentiation of bone marrow cells to macrophages by
M-CSF. The experiments reported in Figure 4.5B were carried out using non-senescent growing
macrophages. It can be seen that mature FMS was still constitutively lost over a period of
5 hours by a process that could not be inhibited by the shedding inhibitor TAPI-0 or by the
kinase inhibitor GW2580.
To confirm the S35 methionine labelling turnover data, the surface loss of FMS was analysed
by live antibody binding. The specificity of the antibody (EBioscience) against the N-terminal
domain of FMS was first checked by comparing the staining of untreated Raw cells with cells
that had lost FMS due to TPA or M-CSF treatment (Figure 4.6A and B). Figure 4.7 shows
that BMM cells lost FMS membrane staining over a 5 hour time course at a similar rate to that
previously determined by S35 methionine analysis.
FMS turnover was next determined in osteoclasts, which are also known to express FMS (Boyle
et al., 2003). Osteoclastogenesis from mouse bone marrow produced an impure population of
primarily BMM cells and osteoclasts which were defined as large, granular multinucleated cells
with at least 5 identifiable nuclei (blue DAPI staining) as shown in Figure 4.8. Osteoclasts de-
rived from mouse bone marrow monocytes also displayed loss of FMS membrane staining (green
staining) over a 5 hour time course in comparison to the stable F-actin (red staining) (Figure
4.9). FMS can be observed undergoing the same rate of loss in the BMM cells surrounding the
impure population of osteoclasts shown in each image in Figure 4.9.
Cell surface biotinylation in BMM cells also confirmed FMS turnover (Figure 4.10). As expected
only the mature cell surface form of FMS was biotinylated (Figure 4.10B) and it was lost over
the 5 hour time course at a similar rate to that determined by S35 labelling. Figure 4.10A shows
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Figure 4.2: RIP inhibition eﬃciency in Raw 264.7 cells. A) Schematic of TAPI-0 and GSI targets
and order of events. B) Eﬀect on FMS levels after a 16 hour treatment with GSI or TAPI-0. C)
GSI and TAPI-0 time course eﬀectivity at shedding inhibition and ICD degradation prevention.
D) Quantification of GSI eﬀectivity after a 5 hour incubation in abrogating the degradation of
the FMS ICD after shedding induction by 100 nM TPA stimulation for 15 minutes. Data is
representative of 3 independent experiments; error bars represent SEM. TAPI-0 and GSI used
at final concentrations of 20 and 5 µM, respectively.
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Figure 4.3: Dual inhibition of shedding and RIP does not abrogate or account for the FMS loss
observed. A) Quantification of S35 methionine pulse-chase blots showing FMS loss over the time
course is not aﬀected by TAPI-0 or GSI. B) Representative S35 methionine blot showing that
constitutive FMS loss is not accompanied by a build-up of the ICD produced by TPA in the
presence of GSI. Lane treatments from the left; lane 1: control cells were vehicle only treated,
lane 2: TPA treatment, lane 3: GSI treatment for 1 hour only, lane 4: GSI pre-treatment for 45
minutes prior to the addition of TPA, lanes 5-8: FMS pulse-chase for the indicated number of
hours in the presence of TAPI-0, lanes 9-12: FMS pulse-chase for the indicated number of hours
in the presence of TAPI-0 and GSI. TAPI-0 and GSI used at final concentrations of 20 and 5
µM respectively. TPA treatment of 100 nM carried out for 15 minutes. Data is representative
of 3 independent experiments; error bars represent SEM.
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Figure 4.4: S35 methionine labelling showing Raw 264.7 and BMM cells both display consti-
tutive turnover in the presence of kinase and shedding inhibitors. Cells were labelled with
radioactive methionine for 3 hours, washed 3 x in PBS and re-incubated in media containing
200 nM GW2580 and 20 µM TAPI-0 for the indicated chase period. Data is representative of
3 independent experiments; error bars represent SEM.
total FMS and tubulin loading controls, the amount of FMS in the control lane was slightly
reduced in comparison to later time points.
We wondered if cell surface proteins might in general be rapidly turned-over in macrophages
because of their phagocytic activity. Figure 4.11 uses FACS analysis to compare the turnover
of CD11b and F4/80, which are commonly used biomarkers for macrophages, with FMS. All
three cell surface proteins were subjected to live antibody labelling using antibodies recognising
extracellular epitopes of the three proteins. Half-life loss from the cell surface can be estimated
at 2-3 hours for FMS, over 5 hours for CD11b and around 2-3 hours for F4/80. We further
analysed turnover by S35 methionine labelling and pulse chase. This showed that CD11b and
F4/80 were relatively unstable compared to another cell surface marker LRP1 (Figure 4.12).
Live antibody labelling and washout with extracellular specific antibodies against FMS and
CD11B in Figure 4.13 show both proteins are lost from the cell surface of BMM over 5 hours.
FMS (green staining) is more stable with weak staining remaining after 5 hours in comparison
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Figure 4.6: Specificity of the FMS immunofluorescence extracellular antibody in cells stimulated
with TPA or M-CSF. Raw 264.7 cells were incubated for 20 minutes at 37◦C with an antibody to
the extracellular domain of the FMS receptor. Cells were then washed in PBS and re-incubated
in media at 37◦C and stimulated with A) 100 nM TPA for 15 minutes or B) 5 x 103 U/ml M-CSF
for 30 minutes prior to fixation, staining and confocal analysis. FMS staining is represented in
red, and nuclei stained with DAPI in blue. Scale bars depict 50 and 5 µm for wide and zoomed
frames respectively. 102
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Figure 4.8: Osteoclastogenesis from mouse bone marrow monocytes. Progenitor cells were
diﬀerentiated with 40 ng/ml RANKL and 5 x 103 U/ml M-CSF for 2 weeks, media changed
every 2-3 days. Cells were then fixed and stained for F-actin (red) with phalloidin and DAPI
(blue). Osteoclasts were determined as the large multinucleated cells containing 5 or more
nuclei. Image represents a single osteoclast cell containing multiple nuclei Scale bar represents
75 µm.
to CD11b (red staining) which can only be faintly detected after three hours and is completely
absent at 5 hours post wash-out. Both appear to have half-lives of sub-3 hours from the
immunofluorescence images presented here. There is a slight discrepancy between the results
for CD11b in Figure 4.11 with Figures 4.12 and 4.13. This may attributable to a certain amount
of non-specific binding of the CD11b antibody in Figure 4.11.
The c-KIT and VEGFR2 receptors expressed in the MO7E cell line and HUVECs respectively
were subsequently analysed for their stability (Figure 4.14). Both receptors were unphosphory-
lated in the absence of exogenous ligand addition. Sunitinib was determined to fully inhibit the
VEGFR2 phospho signal at a final concentration of 10 nM upon VEGF addition and dasatinib
could fully inhibit c-KIT phosphorylation after SCF stimulation.
The c-KIT receptor in the MO7E cell line in the presence of dasatinib and VEGFR2 receptor
104
in HUVEC’s in the presence of sunitinib were both shown to turnover constitutively by S35
methionine pulse-chase labelling (Figure 4.14) The c-KIT receptor half-life can be estimated to
be between 3-5 hours, while the VEGFR2 receptors half-life can be estimated at approximately
1 hour.
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Figure 4.10: Cell surface biotinylation showing FMS loss over 5 hours. BMM cells were bi-
otinylated with 50 µg/ml of biotin N-hydroxysuccinimide ester for 15 minutes at RT prior to
reaction quenching and chasing for the indicated times. A) 2% of the total lysate was subject
to western blotting to assay total FMS levels. B) Cell lysates were then immunoprecipitated
for FMS and immunoblotted with streptavidin.
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Figure 4.11: FACS analysis showing surface loss of three macrophage markers. Live binding of
antibodies against the extracellular domains of FMS, CD11b and F4/80 for 20 minutes prior
to scraping and incubating with the relevant secondary antibody or chasing with fresh media
for the indicated number of hours. Live Cells were then subject to FACS analysis. Data is
representative of 4-6 independent experiments; error bars represent SEM.
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Figure 4.14: Stability of the KIT and VEGFR2 receptors in M07E and HUVEC cells. Quantifi-
cation of 35 methionine labelling and a representative gel of receptor turnover over the stated
time course. MO7E and HUVEC cells were chased in the presence of 10 nM dasatinib and 10
ng/ml sunitinib, respectively. Cells lysates were subsequently immunoprecipitated for A) KIT
and B) VEGFR2. Representative phosphoblots for both receptors are displayed. Data is repre-
sentative of 6 and 3 independent experiments for A) and B) respectively; error bars represent
SEM.
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4.3 Chapter 4: Discussion
FMS was demonstrated by S35 methionine pulse-chase labelling (Figure 4.1, 4.3 and 4.4), im-
munofluorescence live antibody uptake (Figure 4.7), cell surface biotinylation (Figure 4.9) and
FACS analysis (Figure 4.11) to be constitutively lost from expressing cells in a time-dependent
manner with a half-life estimated at between 1-2 hours. This turnover was unaﬀected by shed-
ding (Figures 4.1, 4.3 and 4.4), RIP (Figure 4.3) and kinase inhibitors (Figure 4.4). FMS
turnover was shown to occur in the Rat2c-FMS (Figures 3.1 and 3.2), BMM (Figures 4.1 to
4.7, 4.10 and 4.11), osteoclasts (Figure 4.34) and Raw 264.7 cells (Figures 4.1, 4.3, 4.4 and
data not shown). BMM cells in a state of senescence or growth phase were both found to turn
FMS over at the same rate (Figure 4.5). The macrophage markers, F4/80 and CD11b were
both found to be highly unstable (Figures 4.11 to 4.13) while LRP1 was stable under the same
conditions (Figure 4.12). The c-KIT and VEGFR2 receptors were both also shown to be subject
to constitutive degradation (Figure 4.14).
The constitutive degradation of FMS was not inhibited by either TAPI-0 or batimastat (Figure
4.1), which are both broad spectrum MMP inhibitors. Both inhibitors were shown to be fully
eﬀective at inhibiting TPA-induced FMS shedding after a 5 hour incubation (Figure 4.1A).
S35 methionine labelling was subsequently carried out demonstrating the same rate of FMS
turnover with TAPI-0, batimastat and both combined in the Raw 264.7 cells (Figure 4.1B) and
BMM (Figure 4.1C). This data strongly supports the turnover being observed as independent
of shedding.
Figure 4.3 shows convincingly that the ICD band is readily detectable by S35 methionine la-
belling when shedding is induced in the presence of GSI (Figure 4.3B, compare lanes1-4). GSI
is an inhibitor preventing the release of the FMS ICD from its membrane tether after shedding
induction and therefore its rapid proteasomal degradation (Figure 3.18). As data from Figure
4.2D demonstrates that GSI treatment stabilises the ICD with high eﬃciency (consistently over
90%), it follows that if shedding was primarily responsible for FMS loss and both broad spec-
trum shedding inhibitors tested were ineﬃcient we would expect to see a corresponding ICD
band. Therefore as an ICD band corresponding to the amount of mature receptor lost over
the time course is not observed (Figure 4.3), this provides strong evidence that shedding is not
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accountable for the constitutive FMS loss observed by the S35 methionine labelling experiments.
It was next tested whether autocrine stimulation could account for the FMS loss observed in both
the Raw 264.7 and BMM cells. Figure 4.4 demonstrates the same rate of FMS turnover in the
presence of shedding and kinase inhibition using GW2580 (optimised previously, Figure 3.11).
In support of this FMS was not phosphorylated in Raw 246.7 and BMM cells in the absence
of M-CSF. This confirms by S35 methionine pulse-chase labelling that the FMS receptor loss is
occurring by a third mechanism, distinct from the shedding and ligand-induced pathways.
Live antibody binding was used to look at FMS turnover in mouse osteoclasts (Figure 4.9).
Diﬀerentiated osteoclasts were defined as the large multinucleated cells containing greater than
or equal to 5 nuclei, with many cells having 10 or more nuclei (Figure 4.8). A pure population of
osteoclasts was not achievable with the protocol used, so FMS turnover analysis was restricted
to immunofluorescence experiments. Contaminating BMM cells in the osteoclastogenesis dif-
ferentiation experiment were used as additional controls within the experiment to compare the
FMS turnover in both cell types. Both cell types demonstrated FMS loss occurring at a similar
rate to previous results (Figure 4.9).
It was considered whether the general high phagocytic activity of macrophages could account
for the FMS loss observed. This was tested by analysing the stability of other macrophages
markers and cell surface proteins in Figures 4.11 to 4.13. We determined that the well-known
macrophage markers F4/80 and CD11b were relatively unstable, however LRP1 was relatively
stable (Figure 4.12). Literature reviewing of this hypothesis demonstrated that macrophage cell
surface proteins were generally highly stable (as in other cell types) with iodination analysis
of cell surface proteins confirming this (Kaplan et al., 1979) along with other global analysis
research carried out (Schwanhausser et al., 2011).
The low density lipoprotein (LDL) receptor 1 (LRP1) binds apolipoprotein E, and is involved
in a wide range of biological eﬀect including lipoprotein metabolism, protease degradation,
activation of lysosomal enzymes and endocytosis of some membrane proteins (Lillis et al., 2008).
F4/80 also known as, EGF-like module containing mucin-like hormone receptor-like 1 (EMR1),
is a member of the EGF-TM7 family of GPCRs. Due to its structure it is predicted to play a
role in adhesion and as a signalling regulator, however its ligand remains unknown and it has not
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yet been shown if it is coupled to any G-proteins (Gordon et al., 2011). CD11b, also known as
MAC-1 and integrin αM, is an integrin that is known to heterodimerise with CD18, forming the
complement receptor 3 complex (CR3) which is able to bind many diﬀerent ligands including
LPS and complement activating factors. It also plays a role in the adhesion and migration of
leukocytes in an inflammatory response. The lack of knowledge about the biology of F4/80
and CD11b which makes it diﬃcult for us to conclude whether their instability is due to their
functions, ligand-stimulation or if they are targeted by the constitutive pathway.
To explore the possibility of the constitutive pathway targeting other cell surface proteins, two
RTKs, which have well characterised biology, were next subject to half-life turnover analy-
sis. The c-KIT and VEGFR2 receptors were both implicated as possible constitutive pathway
targets by previous cycloheximide data (Dr Russell, data not shown). S35 methionine pulse-
labelling data shown in Figure 4.14 demonstrates the constitutive turnover of both RTKs in the
absence of ligand stimulation interference. The c-KIT receptor expressed endogenously in the
M07E cell line in the presence of dasatinib (Figure 4.14A) and the VEGFR2 receptor expressed
endogenously in HUVEC cells in the presence of sunitinib (Figure 4.14B) were shown to have
half-lives of 3-5 hours and 1 hour respectively. Turnover of both receptors was determined to
occur at the same rate in the presence or absence of the relevant kinase inhibitor or TAPI-0
(data not shown).
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Chapter 5
Mechanism of the Constitutive Degradation
Pathway
5.1 Chapter 5: Introduction
Internalisation of activated RTKs by endocytosis is an essential process (Lemmon and Sch-
lessinger, 2010; Mellman and Yarden, 2013; Miaczynska, 2014) and is tightly regulated to avoid
excessive signalling, a process linked to multiple human diseases.
The mechanisms of endocytosis are broadly divided into two groups, phagocytosis and pinocyto-
sis. Phagocytosis is the internalisation of large particles or pathogens and is generally performed
by professional phagocytic cells such as monocytes, macrophages and neutrophils (Conner and
Schmid, 2003). Pinocytosis is the internalisation of small solutes and particles and is further
divided into distinct mechanisms of endocytosis including macropinocytosis, clathrin-dependent
endocytosis, caveolin-dependent endocytosis and the least well characterised pathway (gener-
ally characterised in terms of endocytosis negative for the mentioned mechanisms) (Hanson and
Nicols, 2009)) clathrin- and caveolin-independent endocytosis (Conner and Schmid, 2003; Le
Roy andWrana, 2005; Mayor and Pegano, 2007). This clathrin- and caveolin-independent mech-
anism of endocytosis can also be further subdivided into dynamin-dependent or independent
(Kirkhan and Parton, 2005; Mayor and Pagano, 2007).
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Despite these distinct mechanisms of endocytosis receptors have been demonstrated as being
able to undergo several of the endocytic pathways (Gok and Sorkin, 2013) and one receptor
can undergo a diﬀerent endocytic route depending on a whole range of factors including cell
type, ligand type and concentration, co-factor binding and even cellular stress (Miaczynska,
2014). Upon internalisation the receptor:ligand complex is subject to one of three possible
outcomes, receptor recycling, entry into signalling endosomes or transport into MVBs and
subsequent lysosomal degradation (Zwang and Yarden, 2009). These separate compartments
are characterised by markers such as EEA1, Rab4, Rab5, Rab7, Rab11 and proteins such as
LAMP1 or 2 (Le Roy and Wrana, 2005; Zwang and Yarden, 2009; Sorkin and Goh, 2009).
Previous chapters have shown the constitutive degradation of the FMS receptor. Having char-
acterised its loss from the cell surface in Chapter 4 we next explored the mechanism of this
protein turnover in cells.
5.2 Chapter 5: Results
The lysosomal inhibitor, methylamine was demonstrated in Figure 5.1A to induce a concentration-
dependent accumulation of FMS over 5 hours in the Rat2c-FMS cell line. Two kinase impaired
FMS mutants, K616A (middle panel) and G589A (bottom panel) showed the same eﬀect at
similar levels to the wild-type protein. Western blot data from Figure 5.1A was confirmed by
immunofluorescence in Figure 5.1B showing a large accumulation of FMS staining in the per-
inuclear region upon methylamine treatment of cells stably expressing the wild-type or FMS
mutants.
A range of FMS intracellular domain deletion mutants were next tested for constitutive lysoso-
mal degradation (Figure 5.2). Mutants included deletions of the kinase insert (∆KI), juxtamem-
brane (∆JMR), kinase domain (∆KD) and C-terminal tail. A methylamine titration was shown
to build-up FMS in a concentration dependent manner for all mutants tested (Figure 5.2A). All
mutants displayed the same perinuclear FMS build up as the wild type receptor (Figure 5.2B).
This data corresponds well to the cycloheximide data of the kinase impaired mutants and the
domain deletion mutants shown in Figure 3.2, Chapter 3.
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Figure 5.1: Kinase impaired FMS mutants are constitutively degraded via the lysosome. Rat2
fibroblasts expressing the wild-type c-FMS, or two kinase impaired mutants, kinase dead 1
(K616A mutation) and kinase dead 2 (G589A mutation). Cells were treated for 5 hours with
the indicated concentration of methylamine (MA) for A) 5 hours and subject to western blotting
analysis or B) 3 hours and subject to immunofluorescence analysis. FMS staining is represented
in red, and nuclei stained with DAPI in blue.
To elucidate the mechanism of constitutive FMS degradation the colocalisation studies in Fig-
ures 5.4 to 5.9 were performed. Prior to this antibody specificity was validated in Figure 5.3.
Characterisation of the human FMS extracellular antibody was performed in a similar manner
to that carried out previously in Figure 4.6, Chapter 4. Untransfected Rat2 fibroblasts alone
were used as a negative control and remained unstained as expected (Figure 5.3, left image).
Stimulation for 30 minutes with both TPA and M-CSF demonstrated a reduction in staining
compared to the untreated Rat2c-FMS cells (Figure 5.3, compare images 2-4). The extent of the
knockdown is comparable to the levels observed by western blotting data (Figure 3.11, Chapter
3).
Treatment of Rat2c-FMS cells with both leupeptin and methylamine for 3 hours results in a
pronounced accumulation of the FMS receptor in cells in distinct intracellular compartments
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Figure 5.2: FMS intracellular domain deletion mutants are constitutively degraded via the
lysosome. Wild type c-FMS and intracellular deletion mutants of the kinase insert (∆ KI),
juxtamembrane region (∆ JMR), kinase domain (∆ KD) and C-terminal domain were treated
with the indicated concentration of methylamine (MA) for A) 5 hours and subject to western
blotting analysis or B) 3 hours and subject to immunofluorescence analysis. FMS staining is
represented in red, and nuclei stained with DAPI in blue.
(Figure 5.4A). The leupeptin treated Rat2c-FMS cells caused clustering of FMS into large spher-
ical structures distributed throughout the cell, with a greater number in a perinuclear region of
the cell (middle panel). Methylamine treatment resulted in FMS intracellular clustering in the
perinuclear region in very large ‘cauliflower-like’ clusters, very distinct from the leupeptin build
up. The Raw 264.7 cells displayed no obvious increase in FMS staining after the same inhibitor
treatments (Figure 5.4B).
Use of live antibody binding to FMS and the lysosomal stain, lysotracker were used to analyse
the route of constitutive FMS degradation (Figures 5.5 to 5.9). A control experiment showed
that lysosomal staining was aﬀected by both leupeptin and methylamine treatment of Rat2
fibroblasts (Figure 5.5). Untreated cells on average contained 24 detectable lysosomes (left
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Figure 5.4: Treatment with leupeptin and methylamine over 3 hours results in accumulation
of FMS in the Rat2c-FMS. A) Rat2c-FMS cells and B) Raw 264.7 cells were untreated or
treated with 100 µg/ml leupeptin or 10 mM methylamine for 3 hours in the presence of an
antibody specific to the extracellular domain of FMS. Cells were then fixed, subject to standard
immunofluorescence protocols and analysed by confocal microscopy. FMS (green), DAPI (blue).
Scale bar for Rat2c-FMS and Raw 264.7 cells depicts 10 and 5 µm, respectively. Box in the end
panel of A) represents an extended zoom of the FMS build up distribution.
panel), upon a 3 hour leupeptin treatment this number increased to 65 detectable lysosomes
per cell (middle panel). A 3 hour methylamine treatment however virtually eradicated lysosomal
staining, reducing the number of detectable lysosomes to approximately 7 per cell, under half of
the control cells (right panel). The lysosomes in the methylamine treated cells were also much
smaller and less intensely stained than control cells.
The constitutive pathway mechanism was next examined in more detail by colocalisation studies
with Rab7, EEA1 and lysotracker (Figure 5.6). Both EEA1, lysosomal and Rab7 compartments
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Figure 5.5: Rat2c-FMS treated with two lysosomal inhibitors for 3 hours display diﬀerent eﬀects
on lysotracker staining. Rat2c-FMS cells were pre-treated with 100 µg/ml leupeptin or 10 mM
methylamine prior to the addition of 1 µM lysotracker for 30 minutes (red staining), cell fixation
and confocal analysis. Cell nuclei stained with DAPI (blue). Scale bar indicates 10 µm.
were shown to be positive for internalised FMS, with 60% of EEA1 and 80% of lysosomal
compartments colocalising with FMS. It was not possible to quantitate the co-localisation of
FMS with Rab7 because of its association with a large number of undefinable small cytoplasmic
compartments. FMS colocalisation with each marker can be seen as primarily perinuclear in
location.
Figure 5.7 and 5.8 examined the colocalisation between lysosomal staining, Rab7 and EEA1
positive compartments and FMS in the presence of methylamine or leupeptin. Leupeptin treat-
ment (Figure 5.7) resulted in an increase in FMS lysosomal colocalisation to approximately
90%, with staining appearing more intense than in the untreated cells. The number of EEA1
compartments positive for FMS appears in IF images to have increased with leupeptin treat-
ment (Figure 5.7); however the quantification of compartmental colocalisation remained similar
to the controls at approximately 60%. The Rab7:FMS colocalisation appears to have also in-
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Figure 5.9: Treatment of Rat2c-FMS cells with leupeptin or methylamine does not increase
the association of FMS with lysosomes or EEA1 positive compartments. Total lysotracker or
EEA1 compartments were counted per cell and the number of these that were positive for FMS
staining was calculated. Quantification represents the mean with SEM error bars where n=3
with 10 cells/experiment counted. 200-400 endosomes counted for the lysotracker experiment
and 1500-2000 endosomes included per experimental condition. Statistical analysis performed
using one-way ANOVA.
creased, however again this is likely to be due to an increase in the total FMS levels present in
the cells.
Methylamine treatment (Figure 5.8) reduced the lysosomal staining in cells; however colocali-
sation between the remaining lysotracker staining and FMS is constant at approximately 80%.
EEA1:FMS colocalisation was slightly increased by methylamine treatment from approximately
60% to 70%. Rab7 colocalisation appears reduced by the methylamine treatment in compari-
son to the control (Figure 5.6) and leupeptin treated cells (Figure 5.7). Colocalisation with all
markers for both inhibitors appears to be in the perinuclear region.
A comparison of the colocalisation percentages between the amount of EEA1 and lysosome
compartments positive for FMS is shown in Figure 5.9. FMS:lysotracker colocalisation (left
graph) shows a slight increase in colocalisation with leupeptin treatment, however this was
not shown to be statistically significant by one-way ANOVA analysis. Methylamine treatment
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resulted in an increase of EEA1 compartments positive for FMS from a mean of 60 to 70%
(right graph), however this increase was shown not to be statistically significant by one-way
ANOVA analysis.
Figure 5.12: Endogenous cells do not display a FMS build up with degradation inhibitors
tested. BMM cells treated for the indicated time points with A) 100 µg/ml leupeptin, 20 mM
methylamine or B) a titration of ALLN for 3 hours and subject to western blotting analysis
show no build up in FMS levels. C) BMM or D) Raw 264.7 cells were treated for 3 hours with
1 µM ALLN, 100 µg/ml leupeptin or 20 mM methylamine. FMS staining is represented in
red, and nuclei stained with DAPI in blue. Scale bars depicts 7.5 µm. Figure 51B, C and D
performed by C. Bourgarel.
Rat2c-FMS cells were treated with both methylamine and leupeptin in Figure 5.10 to reproduce
the leupeptin eﬀects seen by immunofluorescence in Figure 5.4A (middle panel) and Figure 5.7.
Western blotting analysis demonstrates a slight accumulation of mature FMS over the 24 hour
time course with the methylamine and to a lesser extent with leupeptin. Both treatments
however result in the accumulation of lower molecular weight bands being detected by FMS C-
128
and N-terminal targeting antibodies. Both inhibitors produced an inhibitor-dependent band
detected by the C-terminal antibody of approximately 44 kDa’s and 50 kDa’s, though the latter
band is less prominent with leupeptin inhibition. The N-terminal FMS antibody produced
two degradation products of approximately 50 kDa’s and 75 kDa’s. The leupeptin treatment
C-terminal antibody blot can be better observed as a time-dependent accumulation with the
lighter exposure (middle panel).
Rat2c-FMS fibroblasts were treated with M-CSF for 30 minutes and their endocytosis and
degradation pathway was analysed by co-localisation studies in Figure 5.11. Rat2c-FMS cells
were all stimulated with M-CSF in the absence (first row) or presence of leupeptin (second
row) or methylamine (third row). Both lysosomal inhibitors display a FMS accumulation in
the same compartments as described previously for the constitutive pathway. FMS colocalised
well with the lysotracker staining (second column) in both the untreated and leupeptin treated
cells, but not the methylamine treated cells which display a highly reduced lysosomal stain-
ing. Colocalisation between FMS and Rab7 (third column) displayed weak colocalisation in
the absence of lysosomal inhibition and upon methylamine treatment yet a more pronounced
colocalisation with leupeptin treatment. FMS:EEA1 colocalisation (fourth column) was similar
to that observed for the constitutive pathway.
Having shown that the Rat2c-FMS cell line displays a build-up in the levels of FMS with
methylamine treatment in Figures 5.1 and 5.2, we next attempted to show the same for the
endogenous Raw 264.7 and BMM cells. A range of inhibitors were tested on these cells (Figure
5.12). Leupeptin and methylamine were repeatedly unable to cause a FMS accumulation by
western blotting in BMM cells over 3 hours treatment (Figure 5.12A) this was also the case
for the Raw 264.7 cells (data not shown). A titration of the proteasomal inhibitor ALLN was
also demonstrated in Figure 5.12B to be unable to prevent the constitutive degradation of the
FMS receptor in BMM cells over a 3 hour treatment. These results were confirmed by western
blotting for the Raw 264.7 cells (data not shown) and also by immunofluorescence staining in
both endogenous cell types tested (Figure 5.12C and D).
The mechanism of endocytosis was next tested using the dynamin inhibitor, Dyngo 4a in Figure
5.13. Dyngo eﬀectivity was confirmed using LHR endocytosis as a positive control. The LHR
can be seen to internalise into clusters upon addition of hCG (human chorionic gonadotrophin),
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Figure 5.14: siRNA knockdowns of clathrin heavy chain, ADAM17, LRP1 and Rab7 do not
result in a significant build-up in FMS levels. Raw 264.7 cells were treated with: A) 4 individual
siRNAs targeting the CHC at a concentration of 20 nM for 48 hours; B) 4 individual and a pool
of all 4 (Mix) siRNAs targeting ADAM17 at a concentration of 50 nM siRNA for 72 hours; C)
a mix of 4 diﬀerent siRNAs targeting LRP1 at a concentration of 20 nM for 48 hours. Rat2c-
FMS cells were treated with D) 4 individual and a pool of all 4 (Mix) siRNAs targeting Rab7
at a concentration of 20 nM for 48 hours. Protein levels were subsequently assessed by western
blotting. Figure 5.14C performed by C. Bourgarel.
one of its known ligands (Figure 5.13A, first and second immunofluorescent images in the panel).
Dyngo treatment alone had no eﬀect upon distribution of the LHR (third image) but inhibited
the clustering and internalisation of the receptor when stimulated with HCG (forth image). The
eﬀect of dingo on the FMS and EGF receptors in response to their ligands was subsequently
analysed Figure 5.13B and C. M-CSF was shown to reduce the levels of mature FMS after 1
and 2 hours, consistent with previous results (Figure 5.13B). Dyngo had no inhibitory eﬀect
upon the M-CSF induced loss of FMS. Stimulation of the Rat2 fibroblasts with EGF for 1 and 2
hours resulted in loss of the EGFR (Figure 5.13C). Pre-treatment with Dyngo failed to inhibit
the EGF-induced degradation of the EGFR.
The mechanism of constitutive endocytosis was next tested using a titration of Dyngo and
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Figure 5.15: MAPKAPK-2 inhibition and staurosporine treatment of endogenous cells does not
aﬀect FMS constitutive turnover. A) Amino acid sequence of human FMS highlighting two
possible MAPKAPK-2 binding consensus motifs (S/D/E-X-X-X-L-L). Transmembrane domain
shown in grey. B) Raw 264.7 cells pre-treated with a titration of SB203580 (µM) or staurosporine
(nM) before 2 hours stimulation with 10 ng/ml LPS. C) Raw 264.7 cells were S35 methionine
labelled and pulse-chased for the indicated time point in the presence of 20 µM TAPI-0 in
addition to either 10 µM SB203580 or 100 nM staurosporine. D) BMM cells were S35 methionine
labelled and pulse-chased for the indicated time point in the absence or presence of 10 µM
SB203580 or 100 nM staurosporine.
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Figure 5.16: FMS, c-KIT and the VEGFR2 levels increase with lysosomal inhibition. Western
blots showing receptor levels with methylamine (MA) treatment; FMS levels after A) a titration
of MA in the Rat2c-FMS and B) a time course in the Hekc-FMS cells. C) C-KIT and D)
VEGFR2 receptors time course. Immunofluorescence images of E) FMS and F) VEGFR2 levels
in the presence of absence of MA for 3 hours. Methylamine concentration unless otherwise
stated is 20 mM. Figures 55A and C-F carried out by Dr A. Russell.
analysed by western blotting (Figure 5.13D) and immunofluorescence (Figure 5.13E). Both
titrations displayed no detectable FMS accumulation.
Knockdown studies using siRNA against the clathrin heavy chain, ADAM17, LRP1 and Rab7
were carried out to further explore the involvement of these proteins in the constitutive degra-
dation of the FMS receptor (Figure 5.14). Eﬀective knockdown of the clathrin heavy chain in
Figure 5.14A was shown for siRNA 1 and 2, neither of which was able to elevate the FMS levels
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in the Raw 264.7 cells. ADAM17 knockdown was achieved to a degree with all siRNAs tested
including the mix of all 4 siRNAs (Figure 5.14B). Knockdown of ADAM17 in Raw 264.7 cells
failed to increase the FMS levels. Knockdown of LRP1 using a mix of 4 diﬀerent siRNAs in the
Raw 264.7 cells was successful (top panel), yet failed to significantly build-up the FMS receptor
considering the rate of its degradation (Figure 5.14C). Knockdown of Rab7 in Figure 5.14D
was successful in the Rat2c-FMS cell line (top panel), however once again failed to convincingly
increase the levels of FMS.
The eﬀect of phosphorylation especially that by the MAPK activated protein, MAPKAPK2 on
the constitutive degradation of FMS was next determined in Figure 5.15. Figure 5.15A shows
the amino acid sequence of the human FMS receptor highlighting two possible MAPKAPK2
motifs (S/D/E-XXX-LL), the first within the kinase domain and the second on the C-terminal
tail. The phosphorylation status of both p38 and MAPKAPK2 were shown to be undetectable in
Figure 5.15B in unstimulated Raw 264.7 cells (lanes 1 and 7). Stimulation with LPS successfully
induced phosphorylation of p38 and MAPKAPK2 (Figure 5.15B, top and middle panel). A
titration of the p38 specific inhibitor, SB203580 (lanes 3-6), and the pan kinase inhibitor,
staurosporine (lanes 9-12) were used to inhibit MAPKAPK2 phosphorylation. These were
successful at all tested concentrations of SB203580 ranging from 5 to 20 µM, and from 10 nM
staurosporine. S35 methionine pulse-chase time courses for both Raw 264.7 (Figure 5.15C) and
BMM cells (Figure 5.15D) in the presence of SB203580 and staurosporine with TAPI-0, show
that the FMS turnover is unaﬀected by the presence of either inhibitor.
Methylamine titrations and time courses were used to determine the mechanism of consti-
tutive degradation of the FMS, VEGFR2 and c-KIT receptors (Figure 5.16). Figure 5.16A
demonstrates the concentration dependent build-up in the FMS receptor upon treatment with
a titration of methylamine. Methylamine time courses show the build-up in FMS levels in the
Hekc-FMS cells (Figure 5.16B), c-KIT levels in the MO7E cells (Figure 5.16C) and VEGFR2
levels in the HUVEC cells (Figure 5.16D). Immunofluorescence images confirmed the methy-
lamine western blot receptor accumulation for FMS and VEGFR2, in the perinuclear region of
cells (Figure 5.16E and F, respectively).
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5.3 Chapter 5: Discussion
In summary, the mechanism of constitutive FMS degradation in Rat-2 fibroblasts was shown
to be dependent upon routing to lysosomes for degradation (Figures 5.1, 5.2, 5.4A and 5.6 to
5.10). Similarly, the constitutive degradation of the c-KIT and VEGFR2 receptors, which are
expressed by the MO7E haematopoietic cell line and HUVEC primary cells respectively, was
mediated by lysosome degradation (Figure 5.16).
The constitutive turnover of FMS was independent of its intrinsic kinase ability (Figure 5.1) and
was not prevented by extensive mutation of the intracellular domains (Figure 5.2). Constitutive
degradation was also not prevented by inhibitors of MAPKAPK2 or the many other kinases that
would be expected to be inhibited by the non-specific kinase inhibitor staurosporine at 100 nM
(Figure 5.15). FMS degradation was shown to be independent of caveolin (Dr A. Russell, data
not shown), dynamin and clathrin-dependent endocytosis (Figures 5.13 and 5.14A), implying
that it is endocytosed by a clathrin-independent mechanism.
5.3.1 Methylamine and leupeptin
Weak bases which are able to inhibit lysosomes (such as the methylamine used here) are capable
of doing so through their intrinsic ability at neutral pHs to be highly lipophilic, therefore are
readily cell and membrane permeable. They accumulate in lysosomal compartments in their
basic state and within this acidic compartment become protonated which alters their state to
hydrophilic preventing their diﬀusion out of the lysosome, therefore resulting in their seques-
tration within this compartment. When a high enough concentration is reached an osmotic
gradient is created, resulting in an influx of water into the lysosomes and their swelling, known
as lysosomal vacuolation (Ohkuma and Poole, 1981). This vacuolation can be observed via the
alteration in FMS staining after methylamine treatment in the Rat2c-FMS fibroblasts in Figure
5.4A (third panel).
Considering the non-specific acid-neutralising eﬀect of methylamine other organelles that are
also weakly acidic are likely to be aﬀected in the same manner as lysosomes. Endosomes and
the Golgi apparatus are weakly acidic (Yamashiro et al., 1987). It is therefore possible that
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methylamine could have an eﬀect on the pH of these organelles. The western blot data shown in
Figures 5.1A and 5.2A appear to support a disruption of the Golgi compartment. Methylamine
titrations show a concentration-dependent increase in the level of immature FMS (as well as
mature), indicating that the drug treatment is interfering with FMS processing.
Leupeptin is a selective inhibitor of the serine and cysteine proteases (including plasmin, trypsin,
papain, calpain and cathepsin B). Immunofluorescence data (using a well validated extracellular
FMS antibody) in Figure 5.4A (middle panel) and Figure 5.7 demonstrates a considerable ac-
cumulation of FMS. However accumulation of the mature receptor after a leupeptin time course
was not observed by western blotting (Figure 5.10). Interestingly however a time-dependent
accumulation of lower molecular weight bands detected by the FMS C- and N-terminal anti-
bodies. This indicates the accumulation of FMS degradation products in the lysosome. The N-
and C-terminal 44 kDa, 50 kDa and 75 kDa fragments detected post inhibitor treatment were
likely to have been processed by another of the lysosomes resident proteases that under normal
conditions would be fully degraded in a serine and cysteine protease-dependent manner. It is
unclear whether the 50 kDa product detected by both antibodies is the same product or two
separate products.
There are multiple families of proteases in endosomes and lysosomes (see Introduction for further
detail) which are all believed to possess highly redundant and overlapping enzymatic activities
(Matthews et al., 2010). Each of the classes of endosomal proteases can be targeted selectively
by small molecule inhibitors (Otto and Schirmeister, 2010). However there is not a commercially
available inhibitor of all the diﬀerent lysosomal enzymes. Kasteren et al., (2011) had developed
an inhibitor of all three of the major protease families residing within the lysosome (serine,
cysteine and aspartic). This newly developed inhibitor would be of great interest for future
work to attempt to inhibit the FMS receptors constitutive degradation in endogenous cell types
and accumulate the full length receptor in the Rat2c-FMS model system.
Both methylamine and leupeptin inhibitors were shown to aﬀect the size and number of internal
vesicles that were stained with lysotracker (Figure 5.5). Treatment with leupeptin was shown
to increase the number of complexes that were stained with lysotracker from mean values of
23 to 65 per cell. This could be a result of organelle saturation with un-degraded protein or
an unknown side-eﬀect of the inhibitor. Methylamine treatment of cells reduced the number
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of stained lysosomes to under half that of untreated cells. Lysosomal staining was achieved
using a lysotracker dye, which similar to methylamine is a highly cell-permeable weak base
conjugated to a fluorescent probe which therefore localises to acidic organelles. The lysotracker
signal was completely eradicated by treatment with methylamine which also localises to acidic
organelles raising their pH. This is likely to be the mechanism behind the lysotracker signal
loss observed here. Despite the change in number and size of lysosomes with the two inhibitors
tested in Figure 5.5 the percentage of lysosomes positive for FMS throughout the treatments
remained consistently at 80% (Figure 5.9) further indicating that FMS is primarily targeted to
this degradation pathway for its constitutive turnover.
The increase in KIT and VEGFR levels upon methylamine treatment (Figure 5.16) were not
as great as might be expected from the half-life measurements of these receptors in the same
cell types (Figure 4.14, Chapter 4). This indicates that methylamine may only have partially
inhibited receptor degradation. A possible reason for this is that many of the enzymes residing
in the lysosome are optimally active at acidic pH; however, they may retain some degree of
function at the raised pH caused by methylamine treatment. This needs to be further assessed
by looking for a build up in their degradation products, as was carried out for the FMS receptor
in Figure 5.10.
5.3.2 Failure to rescue FMS constitutive degradation in endogenous cells
We were unable to inhibit FMS constitutive degradation even partially in Raw 264.7 and BMM
cells with methylamine or leupeptin treatment (Figures 5.4B, 5.12, 5.14 and data not shown).
The full list of inhibitors attempted is shown in Table 5.1. A number of possible explanations
are immediately obvious as to why our attempts have been unsuccessful. The most likely being
the readiness of the endogenous cells to induce FMS shedding in response to many conditions,
especially those linked with stress induction. The use of many of the inhibitors tested are likely
to induce a degree of cellular stress, it could therefore be postulated that this is obscuring pos-
sible positive results. This has been observed with several of the inhibitors utilised including,
MG132, bafilomycin A1, ALLN and Dyngo 4a (see Table 5.1 for further information). Lyso-
tracker incubation of the endogenous cells also frequently resulted in either a reduction in FMS
staining or complete loss of staining (data not shown).
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Table 5.1: Table of various inhibitors used and their eﬀects to inhibit the FMS constitutive
degradation. Raw 264.7 cells used as the endogenous model system for these experiments.
Results using Lactacystin, PD150,606 and 1,10-phenanthroline previously acquired by Dr A.
Russell.
An additional explanation as to why the constitutive pathway was unable to be inhibited in
endogenous cells could be due to their biology. Macrophages as professional phagocytic cells are
extremely eﬃcient at degrading various target molecules in comparison to other non-phagocytic
cells such as the fibroblast model system used here. It has been reported that proteins resident
to the lysosome in macrophages are surprisingly long-lived despite the surrounding proteases
including concentrations up to 100 mg/ml of cathepsin D (Barrett, 1992). Half-lives of two lyso-
somal proteins have been estimated at 3.5 and 1.8 days for β-galactosidase and β-glucuronidase,
respectively (Skudlarek and Swank, 1981). Skudlarek and Swank (1981) also demonstrated their
high rate of synthesis in mouse macrophages in comparison to other cell types. β-glucuronidase
was shown to be synthesized at concentrations 20- to 30-fold greater than mouse liver and kidney
respectively and β-galactosidase was synthesized at a rate of 7- to 10-fold greater than mouse
kidney and liver, respectively. It could be easily imagined that eﬀective inhibition of these cell
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types lysosomes would be very diﬃcult to achieve (this can be visualised by the number and size
of lysosomes stained with lysotracker in the BMM compared to the Rat2 fibroblasts as shown
in Figure 5.17. The inability of our inhibition of FMS constitutive degradation in endogenous
cells is likely to be a combination of ineﬀective inhibition of the required pathway and shedding
induction by the tools being used. We hypothesise that the mechanism of constitutive FMS
degradation is similar for both endogenous and non-endogenous cells.
Figure 5.17: Comparison of lysosomal staining in Rat2c-FMS and BMM cells using lysotracker.
Scale bars depict 10 and 5 µm for the Rat2c-FMS and BMM respectively.
5.3.3 Endocytosis
Results presented here have indicated that the trigger for FMS constitutive endocytosis and
degradation is independent of the receptors intracellular domain. Data shows that intrinsic
kinase inability (Figure 5.1), intracellular domains (Figure 5.2) and activity of various cyto-
plasmic kinases inhibited by SB203580 or pan kinase inhibitor, staurosporine (Figure 5.15) are
uninvolved in the FMS constitutive downregulation.
The constitutive FMS internalisation was shown here to occur via non-clathrin-mediated en-
docytosis as it is independent of clathrin and dynamin (Figure 12D and E, and Figure 13A).
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This mechanism of endocytosis is believed to be slower than clathrin-mediated endocytosis (Gok
and Sorkin, 2013). The EGFR has been shown to undergo clathrin-dependent endocytosis in
response to EGF stimulation (Le Roy and Wrana, 2005; Zwang and Yarden, 2009). However,
results in Figure 5.13C using the dynamin inhibitor, Dyngo 4a display no inhibition of EGFR
degradation in response to EGF stimulation despite verification of the drugs eﬀectivity in Fig-
ure 5.13A. This implies that in response to EGF, the EGFR is not endocytosed in a clathrin
mediated-manner. Further literature research confirmed this result. In response to low levels
of EGF (1.5 ng/ml), the EGFR undergoes clathrin-dependent internalisation but at high levels
of ligand stimulation (20 ng/ml) the receptor has been shown to follow a clathrin-independent
endocytic route. This change in endocytosis route has been implicated as being due to satu-
ration of the clathrin-mediated pathway (Sigismund et al., 2005; Gok and Sorkin, 2013). As
M-CSF induced (Figure 5.13B) or the constitutive (Figure 5.13D and E) FMS degradation was
uninhibited by the presence of a dynamin inhibitor, it implies that FMS endocytosis is solely
mediated by a non-clathrin dependent mechanism.
Constitutively endocytosed FMS was shown to route through EEA1 and Rab7 compartments
prior to delivery to lysosomes for degradation in Figures 5.6 to 5.9. Rab7 is a small GTPase
known to be critical for endocytic traﬃcking and is localised to both early and late endo-
somes (Vanlandingham and Ceresa, 2009). EEA1 is a Rab5 eﬀector protein located on early
endosomes (Wilson et al., 2000; Mu et al., 1995). The EEA1 and Rab7 compartments were
shown to precede the traﬃcking of FMS to lysosomes as colocalisation rates were unaﬀected
by lysosomal inhibitors (Figure 5.9, right graph). Preliminary results analysing the M-CSF in-
duced FMS traﬃcking route (Figure 5.11) indicate that FMS is also routed through EEA1 and
Rab7 compartments before being delivered to the lysosome. Our data indicates that FMS is
routed for degradation by M-CSF through the same traﬃcking route responsible for constitutive
degradation.
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Chapter 6
Receptor Synthesis and Degradation Kinetics
6.1 Chapter 6: Introduction
Cells are known to synthesise many proteins by zero order kinetics in order to maintain protein
levels (Wheatley et al., 1980). This constant synthesis rate does not lead to an increase in the
total protein content of cells, therefore it has been repeatedly theorised that the synthesis rate
is balanced by an equal degradation rate following first order kinetics to maintain protein levels
(Rothman, 2010; Hinkson and Elias, 2011; Wheatley, 2011). This degradation rate has been
reported to increase in non-growing cells (Spencer et al., 1975), indicating that cell cycle stage
or senescence has little eﬀect on the synthesis rate of proteins undergoing zero order synthesis
kinetics.
This seemingly wasteful process has been proposed as essential for cells to adapt to their chang-
ing environments (Schwanha¨usser et al., 2011). A constant synthesis rate of these proteins
would enable a rapid return of protein levels after perturbation in their levels, avoiding the
requirement of complex feedback loop evolution (Hinkson and Elias, 2011). The requirement of
transcription initiation would also be highly likely to slow the return of the protein levels. It
could therefore be envisaged that RTKs that are highly expressed and essential under normal
conditions would be subject to a rapid synthesis and therefore equal degradation rate under
steady state conditions.
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6.2 Chapter 6: Results
Ligand induced receptor knockdown and receptor level recovery was carried out in Figure 6.1,
with the EGFR, PDGFRβ and FMS. EGFR knockdown and receptor level recovery was com-
pared in growing and quiescent Rat2 fibroblasts in Figure 6.1A. The time course demonstrated
a similar knockdown level for both growing and quiescent cells with levels appearing almost
100% recovered by the 9 hour time point post EGF washout. PDGFRβ levels were knocked
down eﬃciently with the concentration of PDGFββ used; however the recovery of its levels were
only partially restored after 24 hours ligand-free recovery time (Figure 6.1B). FMS levels were
knocked down by almost 100% 1 hour post M-CSF washout and levels rapidly recovered com-
pletely within 6 hours (Figure 6.1C). Hela cells treated with EGF displayed a similar knockdown
of EGFR with levels fully recovered after 12 hours EGF washout (Figure 6.1D). The EGFR
receptor appeared to exhibit a return at a similar rate in both Rat2 fibroblasts (Figure 6.1A)
and Hela cells (Figure 6.1D).
The results of Figure 6.1A indicate that the EGFR is synthesised by both growing and quiescent
Rat-2 fibroblasts. In confirmation of this S35 methionine incorporation into the EGFR over 3
hours was shown to be independent of cell confluency in the Rat2 fibroblasts (Figure 6.2). Lane
two appears to have slightly more EGFR present than the other lanes, however the general
background for this lane is proportionally higher, therefore it is likely this is not a genuine
increase in EGFR synthesis levels.
Figure 6.3 shows the levels of the EGFR and FMS after ligand knockdown and recovery and the
rate of receptor synthesis by S35 methionine labelling over this period. Hela cells stimulated with
EGF displayed a time-dependent receptor level recovery over 12 hours (Figure 6.3A, top panel
western blot). The rate of EGFR synthesis can be seen in the S35 methionine representative
blot (third panel) to increase between the stimulated (+) cells and those at 4 and 8 hours post
ligand washout. Quantification shows an 85% peak increase in the rate of synthesis over the
control levels at 4 hours. The synthesis levels can be seen as reducing back to those of the
unstimulated control by 12 hours.
FMS receptor levels after TPA stimulation can be seen as returning back to the control levels
in a time-dependent manner by 4 hours washout (Figure 6.3B, top panel western blot). The
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Figure 6.2: The EGFR synthesis rate is independent of cell confluence. Rat2 fibroblasts were la-
belled with S35 methionine for 3 hours at the indicated cell confluencies, cells were subsequently
lysed, immunoprecipitated for the EGFR, followed by SDS-PAGE separation and autoradiog-
raphy.
synthesis rate can be seen in the S35 methionine representative blot (third panel) to be constant
throughout the time course. Quantification using a combination of TPA and M-CSF knockdown
experiments to determine the FMS synthesis rate confirms a constant synthesis rate for the FMS
receptor in BMM cells.
The rate of S35 methionine label incorporation into FMS was analysed in Figure 6.4. The level
of labelled FMS increased in a time-dependent manner and can be seen to plateau after only 2
to 3 hours. Total FMS levels were shown to be constant by western blot analysis of the whole
cell lysate (middle panel). Overall these results indicate that the steady state levels of FMS
results from matching rates of FMS synthesis and degradation, both of which are likely to be
relatively rapid compared to the EGF or PDGFβ receptors.
Protein degradation is known to follow 1st order kinetics (see Introduction), therefore if receptor
levels are reduced the constitutive degradation rate should also be reduced. Figure 6.5 examines
the eﬀects of a TPA knockdown on FMS stability before receptor levels have returned to normal.
Figure 6.5A and B (left panels) show the western blots of FMS total protein levels after knock-
down with TPA results in a reduction in receptor levels at 1 and 2 hours post washout. The
synthesis rate is shown to be constant by S35 methionine labelling (middle panels). Receptor
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Figure 6.4: S35 methionine analysis of FMS labelling over a time course shows a rapid level
plateau. FMS was labelled with S35 methionine for the indicated time points before lysis
(aliquot retained for western blotting analysis), immunoprecipitation, SDS-PAGE separation
and autoradiography. Total FMS levels were determined by western blotting.
stability was initially assessed for each time point by labelling the cells for 20 minutes and then
chasing with cold methionine for either 5 or 3 hours (Figure 6.5A and B, respectively). The
band intensities of FMS in the first and last lanes appear less intense than the FMS bands
generated following the washout of TPA. This is consistent with the hypothesis that FMS levels
increase (left panels) as a result of a decrease in FMS degradation.
We were concerned that the washout of TPA may not occur quickly. TPA is known to activate
ERK, which in turn is required for ADAM17 activity. ADAM17 activity was therefore indirectly
assessed via pERK levels in Figure 6.6. The time course of FMS return after washout is
shown in the top panel, demonstrating a return to normal receptor levels by 4-6 hours. ERK
phosphorylation is undetectable in unstimulated BMM, however post-TPA washout the levels
of pERK remain slightly higher than the control throughout the time course (Figure 6.6, first
lane).
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Figure 6.6: Western blot analysis of FMS and pERK levels after TPA washout. Cells were
stimulated with 100 nM TPA for 15 minutes prior to washout and incubation in fresh media
for the indicated time points. Cells were lysed and subject to western analysis.
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6.3 Chapter 6: Discussion
We previously established that under normal growing conditions, FMS is subject to constitutive
degradation (Chapter 3), which implies that the maintenance of steady state levels of FMS
requires constant synthesis in order to counteract degradation. Here we looked at the rate of
FMS synthesis by labelling for only 20 minutes, which is too short a time for FMS to enter
the degradation pathway (Morley et al., 1999). We found that the rate of FMS synthesis
was constant irrespective of dramatic changes in the steady state levels of FMS caused by
transient stimulation by TPA (Figure 6.5). This clearly implies that the restoration of FMS
levels following transient downregulation must result from a decrease in the degradation rate
rather than an increase in FMS synthesis. Of course the removal of TPA will prevent degradation
due to shedding and this would be expected to cause an increase in FMS levels. However, it
seems likely that FMS must for a temporary period of time become more stable than normal
in order to be restored to previous levels. This implies that constitutive degradation is also
inhibited following the reduction in FMS levels caused by TPA treatment.
There is good reason to believe that FMS ‘constitutive degradation’ is likely to be inhibited
as a result of reducing FMS steady state levels. By injecting radioactive proteins into cells
and monitoring their degradation or decay, it has previously been established that degradation
follows first order kinetics i.e. the rate of degradation is proportional to the concentration
of protein that is injected (Zavortnik et al., 1979). Consequently, our results are consistent
with the expectation that lowering FMS steady state levels will decrease its rate of constitutive
degradation and therefore promote a return to the previous FMS steady state level.
Figure 6.5 is a preliminary attempt to confirm that the FMS degradation rate is reduced when
its steady state levels are lowered. The results are consistent with this hypothesis, although we
are concerned that the eﬀects of TPA are not easy to wash out and so may be quite long lasting
(Figure 6.6). We are currently repeating this experiment using transient M-CSF stimulation.
Our analysis of the EGF receptor was more complicated in that its rate of synthesis was stimu-
lated approximately two-fold by transient EGF stimulation, which is in agreement with previous
results (Bjorge and Kudlowl, 1987; Seth et al., 1999). It is unclear from there results whether
the observed increase in EGF receptor synthesis alone is enough to restore the receptors levels
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over 12 hours in the absence of a constant ongoing degradation rate (Figure 6.3).
Work carried out in this chapter has attempted to separate how receptor levels are controlled
in cells. Our results using S35 methionine labelling have demonstrated to us that despite cell
cycle stage (BMM cells used have been shown to be cycling or senescent demonstrating the
same results, and EGFR results demonstrated in Figures 6.1A and 6.2), receptors that can be
methionine labelled are being synthesised at a basal rate, however under normal conditions the
levels of receptors do not increase, we hypothesise that the receptors must be degraded at an
equal rate to their synthesis under steady state conditions. Conditions where the receptors
are shown to be subject to reduced levels, such as would occur after ligand stimulation we
would predict that the rate of synthesis either substantially increases to compensate for this
loss enabling receptor levels to return to their pre-knockdown rates, or that the constitutive
degradation must stop until the receptor levels have returned to normal. Results shown in
this chapter have attempted to separate whether levels of FMS and the EGFR are able to
return to normal concentrations after knockdown by synthesis increase, constitutive degradation
reduction or a combination of the two.
Results shown here have demonstrated the eﬀective knockdown of RTK levels using their ligands
to determine their rates of synthesis, this could be extended with further work to determine
their rate of degradation. The levels of the EGFR were demonstrated to return to control
levels within 12 hours post 1 hour EGF knockdown (Figures 6.1D and 6.3A), irrespective of
cell confluence (Figures 6.1A and 6.2). Levels of the FMS receptor were shown to return to
that of the controls level within 4-6 hours post-MCSF washout. This return cannot be solely
attributed to by receptor synthesis as this has been consistently demonstrated as occurring at a
constant rate (Figures 6.3B and 6.5). The EGFR upon ligand stimulation was demonstrated to
induce and increase its own synthesis rate (Figure 6.3A). This synthesis rate change was shown
to increase maximally by an extra 85% above the control at 4 hours post washout. To determine
whether this increase in synthesis alone is enough to restore the receptor levels within 12 hours
back to pre-knockdown levels we need to first determine the EGFR half-life in Hela cells.
FMS synthesis was shown to occur at a constant rate, irrespective of the receptors levels (Figures
6.3B and 6.5). Results from Figure 6.4 show that labelling of the receptor with S35 methionine
reaches a plateau after approximately 2 hours labelling, this indicates that the levels of the
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labelled receptor had reached high enough levels that it is being constitutively degraded from 2
hours. We attempted to determine in Figure 6.5 whether FMS is more stable after knockdown
when levels have not fully recovered yet. This would enable us to determine whether constitutive
degradation of the receptor stops or occurs at a lower rate under lower receptor concentrations.
This would inform us whether the degradation kinetics are occurring at 1st order as we would
predict, or whether they are constant and 0 order. Our results from Figure 6.5 trying to observe a
stabilisation of the receptor after two diﬀerent chase time points proved inconclusive. We believe
this is due to the knockdown mechanism used as indicated by Figure 6.6. TPA activation of
ADAM17 was used for the experiments carried out in Figure 6.5. However our inconclusive
results in Figure 6.5 led us to question whether the TPA washout had fully inactivated shedding.
As ADAM17 activity is diﬃcult to assess and previous results had shown pERK activity as
being required for the FMS shedding (Figure 3.19) ERK activation was looked at over the time
course. Residual ERK activity was clearly observed throughout the time course, despite the
comparatively low levels of ERK, and the unclear direct translation to ADAM17 activity, this
result strongly suggests that TPA is not suitable for use in this set of experiments, especially
considering FMS has been shown to be a very sensitive shedding target. It is likely that our
degradation experiments in Figure 6.5 are obscured by residual shedding activity occurring
during the chase period. These experiments will therefore potentially prove enlightening when
repeated using M-CSF as the receptor level knockdown tool of choice.
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Chapter 7
Final Discussion
7.1 Summary
We have shown that the FMS receptor is constitutively degraded with a half-life of 1-2 hours in
the absence of receptor kinase activity or shedding in a range of cell types (Chapters 3 and 4). We
have demonstrated that the mechanism behind constitutive degradation is clathrin-, caveolin-
and dynamin-independent mediated endocytosis. The endocytosed receptor is routed through
EEA1 positive compartments to Rab7 compartments and finally delivered to the lysosome for
degradation (Chapter 5). This evidence is strongest for the Rat-2 fibroblast model system and
needs strengthening for other cell types such as macrophages.
Chapter 6 examined the relationship between FMS steady state levels and its rate of synthesis.
Interestingly, the rate of FMS synthesis was shown to be constant and independent of FMS
steady state levels. Implying that the loss and restoration of FMS steady state levels that
we observed as a result of transient stimulation with TPA is achieved by changes in the rate
of degradation. We have yet to prove that FMS constitutive degradation is inhibited when
FMS steady state levels are reduced but as previously discussed this is likely to be the case
(Discussion Chapter 6 and see below).
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7.2 Biological role of homeostatic degradation
If the rate of degradation of the FMS receptor is dependent upon receptor concentration then
the term ‘constitutive’ is not an accurate description. We suggest that constitutive degradation
is perhaps better described as homeostatic degradation and that in this role it is an important
buﬀer for receptor levels.
It seems clear that a major function of homeostatic degradation is to prevent receptor overex-
pression, which we have demonstrated through lysosome inhibitor experiments (Figures 5.1, 5.2,
5.10 and 5.16). This raises the question as to why the synthesis of the FMS, KIT and VEGF2
receptors is so vigorous that it requires a degradation mechanism to prevent overexpression.
Figure 7.1i illustrates a theoretical example of two receptors that have the same steady state
levels, one of which is synthesised and degraded at a more vigorous rate.
Figure 7.1ii illustrates that the receptor that has the greater rate of synthesis will reach its
steady state level much faster from low starting levels or following depletion of its normal levels.
It follows that we suspect that receptors that have fast synthesis and degradation rates will be
better suited to undergo rapid changes in their steady state levels during their normal function.
Such receptors may include those that are likely to be subject to transient shedding stimuli.
Receptors known to have short half-lives in the absence of ligand stimulation (see Introduction
for details) have frequently been demonstrated as being subject to ectodomain shedding. Exam-
ples of these receptors are; VEGFR2 (Swendeman et al., 2008), c-KIT (Turner et al., 1995; Cruz
et al., 2004), IL-6R (Chalaris et al., 2010), TrkA (Diaz-Rodriguez et al., 2002), FGFR3 (Degnin
et al., 2011), c-Met (Galvani et al., 1995; Nath et al., 2001) to mention a few examples. The
link between high receptor turnover under steady-state conditions and shedding is consistent
with the suggestion given above. The EGF receptor does not undergo shedding and is relatively
stable with an estimated half-life in the order to 10 to 20 hours according to cell type in the
absence of ligand stimulation (Decker et al., 1992; Seth et al., 1999). It is not yet clear but the
restoration of EGFR levels following transient EGF stimulation may also be dependent upon
the inhibition of degradation as well as an increase in synthesis rate (Rothman, 2010; Hinkson
and Elias, 2011; Wheatley, 2011; Clayton and Beynon, 2012).
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Figure 7.1: Schematic of protein synthesis and degradation kinetics
7.3 Protein turnover
In general the cellular proteome has been shown to be continually synthesised and degraded in
cells under steady state conditions by the pioneering work of Schoenheimer in the late 1930s.
This dynamic process is known as protein turnover. Initial studies carried out on this process
used 15N labeled amino acids to explore amino acid biosynthesis and recycling (Schoenheimer
et al., 1938), later with the development of 2D electrophoresis the degradation of hundreds of
unknown proteins was determined (Larabee et al., 1980). Antibody based detection technology
enabled the identification and furthering of this field soon after. The net protein levels (defined
as [P] below) in cells under steady state conditions remain constant, demonstrating the existence
of an equilibrium between rates of synthesis (Ksyn) and degradation (Kdeg) occurring (Foster
et al., 1939; Ratner et al., 1940; Schoenheimer, 1942). A simple model for protein turnover
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according to Claydon and Beynon (2012) is given by the equation:
[P] = Ksyn / Kdeg
More elaborate mathematical models of protein degradation assume that protein synthesis fol-
lows zero order kinetics i.e. is independent of the concentration of protein or product (Wheatley
and Inglis, 1973) whereas it is assumed that degradation is dependent upon protein concentra-
tion and therefore occurs by first order kinetics (Wheatley and Inglis, 1986; Rothman, 2010;
Hinkson and Elias, 2011; Wheatley, 2011).
Schwanha¨usser et al., (2011) found that regulatory genes were more likely to have short mRNA
and protein half-lives, and that genes with stable mRNA and unstable proteins were notably
largely extracellular proteins. The authors also found the majority of proteins to be stable with
protein stability surpassing mRNA stability by five times, with conservative half-lives estimated
at 46 and 9 hours, respectively. The majority of proteins were found to be stable except for
those that are required to respond rapidly to stimuli or alterations in cellular environment.
These findings have also been frequently determined experimentally or theoretically elsewhere
(Berlin and Schimke, 1965; Vogel and Marcotte, 2012; Claydon and Beynon, 2012; Ahmad and
Lamond, 2013).
It has also been suggested multiple times that proteins with short half-lives are keystone com-
ponents and regulators in cells. Therefore their levels can often be subject to perturbation
upon changes in cellular environment (Rothman, 2010; Schwanha¨usser et al., 2011; Claydon
and Beynon, 2012; Vogel and Marcotte, 2012). Based on this model a cell would be able to
rapidly restore the levels of such a protein that has had its levels perturbed if its basal synthesis
rate was high. Therefore a reduction or partial suspension in its degradation rate would enable
rapid return to normal levels.
The FMS receptor has been demonstrated to fall into the category defined by Schwanha¨usser
et al., (2011) of having stable mRNA (Dr Russell, data not shown) and unstable protein. If
FMS behaves like all previously studied proteins then it is likely to be degraded by first order
kinetics. We predict that when the levels of FMS are knocked down by shedding induction
or ligand-induced degradation that the constitutive degradation of the receptor is temporarily
155
disabled, which enables its levels to return rapidly to steady-state levels. We attempted to
determine whether newly labelled receptor would be more stable after steady state level knock
downs but were not able to confirm this convincingly, which we believe to be due to technical
diﬃculties such as those discussed in Chapter 6.
Literature research has highlighted selected other candidates that appear to also be subject to
constitutive/homeostatic degradation. The inhibitor of NFκB, IκBα has been implicated to
undergo an unstimulated constitutive degradation in a calpain-dependent manner in primary
human T lymphocytes and B cell lines (Shumway and Miyamoto, 2004; Ponnappan et al., 2005).
The role of this protein degradation was speculated to enable the activity of the transcription
factor, NFκB in unstimulated cells by controlling the levels of its key regulator by the inhibitor
proteins degradation (Ponnappan et al., 2005). This would enable the cell to dynamically alter
the activity of NFκB depending on cell environment by controlling the protein levels of its
inhibitor by degradation of a constantly available protein.
Another protein suggested to be regulated to homeostatic degradation depending on the cellular
condition is the AMPA glutamatergic receptor (Hou et al., 2011). This receptor was demon-
strated in individual synapses to be highly stable with a half-life of 20-30 hours in the absence of
stimuli; however upon stimulation with light (a selective activator of the presynaptic neuronal
terminal) the receptor became highly unstable, indicating its extensive homeostatic regulation
in response to various environmental changes.
7.4 Future Work
1. To confirm that the FMS receptors degradation is dependent on receptor concentration.
2. To confirm whether the EGFR is subject to homeostatic degradation or whether the
increase in EGFR synthesis induced by the transient EGF stimulation is enough to fully
restore levels after knockdown in the time-frame observed.
3. To support the view that endogenous FMS is constitutively degraded via the lysosome
in primary BMM cells by colocalisation studies of live-bound receptor with the lysosomal
proteins LAMP1 and 2.
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4. To identify other proteins that may be subject to constitutive degradation by 2D gel
electrophoresis and mass spectrometry analysis of proteins with short half-lives.
5. To identify genes that mediate the homeostatic degradation of FMS through siRNA
screens.
6. Similarly to screen small molecule inhibitors for those that increase FMS protein levels.
7. Determine if any of the genes involved in this mechanism of downregulation are dysregu-
lated in disease.
8. Use of a more universal lysosomal inhibitor developed by Kasteren et al., (2012) in endoge-
nously expressing cells and the Rat2c-FMS model system to inhibit FMS degradation.
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